<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27542236</article-id><article-id pub-id-type="pmc">5342470</article-id><article-id pub-id-type="publisher-id">10171</article-id><article-id pub-id-type="doi">10.18632/oncotarget.10171</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper: Gerotarget (Focus on Aging)</subject></subj-group></article-categories><title-group><article-title>Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: a randomized intervention trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Graff</surname><given-names>Ingvild Eide</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>&#x000d8;yen</surname><given-names>Jannike</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kjellevold</surname><given-names>Marian</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fr&#x000f8;yland</surname><given-names>Livar</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gjesdal</surname><given-names>Clara Gram</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Alm&#x000e5;s</surname><given-names>Bj&#x000f8;rg</given-names></name><xref ref-type="aff" rid="A4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rosenlund</surname><given-names>Grethe</given-names></name><xref ref-type="aff" rid="A5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lie</surname><given-names>&#x000d8;yvind</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> National Institute of Nutrition and Seafood Research (NIFES), Bergen, Norway</aff><aff id="A2"><sup>2</sup> Department of Rheumatology, Haukeland University Hospital, Bergen, Norway</aff><aff id="A3"><sup>3</sup> Department of Clinical Science, University of Bergen, Bergen, Norway</aff><aff id="A4"><sup>4</sup> Hormone Laboratory, Haukeland University Hospital, Bergen, Norway</aff><aff id="A5"><sup>5</sup> Skretting Aquaculture Research Centre, Stavanger, Norway</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Jannike &#x000d8;yen,</italic><email>jannike.oyen@nifes.no</email></corresp></author-notes><pub-date pub-type="collection"><day>25</day><month>10</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>14</day><month>8</month><year>2016</year></pub-date><volume>7</volume><issue>43</issue><fpage>69200</fpage><lpage>69215</lpage><history><date date-type="received"><day>9</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>9</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 Graff et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Suboptimal vitamin D status is common among humans, and might increase bone resorption with subsequent negative effects on bone health. Fatty fish, including Atlantic salmon, is an important dietary vitamin D source. However, due to a considerable change in fish feed composition, the contribution of vitamin D from salmon fillet has been reduced. The main objective was to investigate if intake of vitamin D<sub>3</sub> enriched salmon or vitamin D<sub>3</sub> tablets decreased bone biomarkers (urinary N-telopeptides, deoxypyridinoline, serum bone-specific alkaline phosphatase, and osteocalcin) compared to a low vitamin D<sub>3</sub> intake. The 122 healthy postmenopausal women included in this 12 weeks intervention trial were randomized into four groups: three salmon groups (150 grams/two times/week) and one tablet group (800 IU vitamin D and 1000 mg calcium/day). The salmon groups also received calcium supplements. The salmon had three different vitamin D<sub>3</sub>/vitamin K<sub>1</sub> combinations: high D<sub>3</sub>+high K<sub>1</sub>, low D<sub>3</sub>+high K<sub>1</sub>, or high D<sub>3</sub>+low K<sub>1</sub>. Increased intake of salmon containing high levels of vitamin D<sub>3</sub> (0.35-0.38 mg/kg/fillet) and supplements with the same weekly contribution had a positive influence on bone health as measured by bone biomarkers in postmenopausal women. Consequently, an increased level of vitamin D<sub>3</sub> at least to original level in feed for salmonids will contribute to an improved vitamin D<sub>3</sub> status and may improve human bone health.</p></abstract><kwd-group><kwd>Atlantic salmon</kwd><kwd>bone health</kwd><kwd>vitamin D</kwd><kwd>vitamin K</kwd><kwd>bone biomarkers</kwd><kwd>Gerotarget</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Proper nutrition plays a crucial role in both the prevention and the treatment of osteoporosis. In addition to calcium, vitamin D from dietary or supplement sources have historically been the major therapeutic focus [<xref rid="R1" ref-type="bibr">1</xref>]. Suboptimal vitamin D status is common among humans in general [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>]. Fatty fish like Atlantic salmon (<italic>Salmo salar</italic>) is one of the very few natural dietary sources of vitamin D [<xref rid="R4" ref-type="bibr">4</xref>]. However, due to a considerable change in fish feed composition with less marine and more plant based ingredients the contribution of vitamin D from salmon fillet has been reduced. Thus, the content of vitamin D in commercial farmed Atlantic salmon is relatively low [<xref rid="R4" ref-type="bibr">4</xref>]. Fatty fish have also a naturally high content of long-chain omega-3 polyunsaturated fatty acids (LC-PUFA) which have been suggested to have a role in the prevention of osteoporosis due to several mechanisms, including its altering of the immune function [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>].</p><p>The prevalence of osteoporosis [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref>] and osteoporotic fractures [<xref rid="R9" ref-type="bibr">9</xref>] are especially high in Norway, and low vitamin D levels have been observed in patients with osteoporosis [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R10" ref-type="bibr">10</xref>], distal radius fracture [<xref rid="R10" ref-type="bibr">10</xref>], and hip fracture [<xref rid="R11" ref-type="bibr">11</xref>]. Further, general findings from prospective studies in community-dwelling populations indicate that low concentrations of vitamin D are associated with future fracture risk, and randomized controlled studies shows fracture preventive effects of combined supplement with vitamin D and calcium [<xref rid="R12" ref-type="bibr">12</xref>]. In addition, the general elderly population is at risk of vitamin D deficiency [<xref rid="R13" ref-type="bibr">13</xref>]. Osteocalcin is produced by osteoblasts and incorporated into the bone matrix. It is released into the circulation from the matrix during bone resorption and, therefore, is considered a marker of bone turnover rather than a specific marker of bone formation [<xref rid="R14" ref-type="bibr">14</xref>, <xref rid="R15" ref-type="bibr">15</xref>]. Osteocalcin is carboxylated by the vitamin K-dependent &#x003b3; carboxyglutamic acid [<xref rid="R16" ref-type="bibr">16</xref>] and this process is critical for osteocalcin's ability to bind hydroxyapatite. In humans, the fraction of the circulating osteocalcin that is not &#x003b3;-carboxylated (GLU/GLA) is used as a biomarker of vitamin K status [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. Low levels of vitamin K<sub>1</sub> and K<sub>2</sub> has been observed in osteoporotic patients [<xref rid="R19" ref-type="bibr">19</xref>, <xref rid="R20" ref-type="bibr">20</xref>], and low dietary intake of vitamin K<sub>1</sub> has been associated with low bone mineral density (BMD) and increased risk of hip fracture [<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>]. Furthermore, it is shown that undercarboxylated osteocalcin increases with age [<xref rid="R23" ref-type="bibr">23</xref>], and high levels are associated with both lower BMD and increased risk of hip fracture [<xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>]. In studies where calcium, vitamin D or vitamin K have been given as supplements to osteoporotic rats [<xref rid="R26" ref-type="bibr">26</xref>] or women [<xref rid="R27" ref-type="bibr">27</xref>], the results show a synergistic effect of giving calcium, vitamin D and vitamin K simultaneously. However, as far as we know, this has not been investigated as part of the diet in an intervention study.</p><p>Bone turnover is also reflected by different bone formation biomarkers such as bone alkaline phosphatase (BAP) [<xref rid="R28" ref-type="bibr">28</xref>], and bone resorption biomarkers, such as telopeptide (NTx) and deoxypyridinoline (DPYD) [<xref rid="R29" ref-type="bibr">29</xref>]. Anti-resorption osteoporosis treatment with bisphosphonates provides a decrease in bone turnover, both resorption and formation parameters, followed by an increase in BMD [<xref rid="R30" ref-type="bibr">30</xref>].</p><p>In most intervention studies where changes in BMD have been investigated as part of osteoporosis treatment, the intervention periods are at least around nine months [<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref>]. Thus, we aimed to have the focus on bone biomarkers and nutrition status where alterations previously have been detected within one month and more after osteoporosis drug treatment [<xref rid="R33" ref-type="bibr">33</xref>]. Therefore, the main aim of the present intervention trial was to investigate if intake of vitamin D enriched Atlantic salmon or vitamin D tablets decreased the bone turnover markers (urinary NTx, DPYD, s-BAP, and osteocalcin) compared to a low vitamin D intake. Secondary aim was to examine potential effects of increased intake of tailor-made Atlantic salmon on vitamin K status measured by s-undercarboxylated osteocalcin (GLU), s-carboxylated osteocalcin (GLA), and the GLU/GLA ratio. This also includes nutritional status measured by s-25-hyroxyvitamin D (25(OH)D), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), as well as BMD, body fat mass and lean mass.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Tailoring of farmed Atlantic salmon</title><p>The different levels of vitamin D<sub>3</sub> and K<sub>1</sub> in the fish feed were reflected in the salmon fillet with increasing fish weight (Figure <xref ref-type="fig" rid="F1">1</xref>). The desired levels of vitamin D<sub>3</sub> of at least 0.25 mg/kg were achieved according to the study design. There was also an increased level of vitamin K<sub>1</sub> in the fillet according to the design.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>The different level of vitamin D(mg/kg)in the salmon fillet, time (October 2008 to January 2009) and mean salmon weight according to the feed levels/groups</title><p>HD/HK, salmon fed high content of vitamin D<sub>3</sub> and K<sub>1</sub>; HD/LK, salmon fed high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>; LD/HK, salmon fed low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>.</p></caption><graphic xlink:href="oncotarget-07-69200-g001"/></fig></sec><sec id="s2_2"><title>Characteristics of the participants</title><p>Baseline (pre-intervention) characteristics of the study population in total and by intervention group are given in Table <xref ref-type="table" rid="T1">1</xref>. There were no significant differences between the groups for any of the included variables at pre-intervention. The median (interquartile range [IQR]) age of the 122 included women were 55.0 (5.0) years, and their body mass index (BMI) were 24.4 (5.0) kg/m<sup>2</sup> at baseline.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline characteristics of all participants and by intervention group. Data are given as median (IQR) if not other is indicated</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Overall<break/>(n=122)</th><th align="left" valign="top" rowspan="1" colspan="1">Tablets<xref rid="tfn_001" ref-type="table-fn"><sup>a</sup></xref><break/>(n=30)</th><th align="left" valign="top" rowspan="1" colspan="1">HD/HK<xref rid="tfn_002" ref-type="table-fn"><sup>b</sup></xref><break/>(n=31)</th><th align="left" valign="top" rowspan="1" colspan="1">LD/HK<xref rid="tfn_003" ref-type="table-fn"><sup>c</sup></xref><break/>(n=30)</th><th align="left" valign="top" rowspan="1" colspan="1">HD/LK<xref rid="tfn_004" ref-type="table-fn"><sup>d</sup></xref><break/>(n=31)</th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_005" ref-type="table-fn"><sup>e</sup></xref></th></tr></thead><tbody><tr><td colspan="7" align="left" valign="top" rowspan="1">Demographics</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Age (year)</td><td align="left" valign="top" rowspan="1" colspan="1">55.0 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">56.5 (7.0)</td><td align="left" valign="top" rowspan="1" colspan="1">54.0 (6.8)</td><td align="left" valign="top" rowspan="1" colspan="1">54.5 (4.3)</td><td align="left" valign="top" rowspan="1" colspan="1">56.0 (5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.285</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Body weight (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">68.2 (15.3)</td><td align="left" valign="top" rowspan="1" colspan="1">67.7 (16.9)</td><td align="left" valign="top" rowspan="1" colspan="1">73.1 (14.8)</td><td align="left" valign="top" rowspan="1" colspan="1">68.8 (16.8)</td><td align="left" valign="top" rowspan="1" colspan="1">65.5 (11.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.204</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">24.6 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">24.1 (6.6)</td><td align="left" valign="top" rowspan="1" colspan="1">25.8 (5.1)</td><td align="left" valign="top" rowspan="1" colspan="1">24.6 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">23.8 (3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.137</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Current smoking, N (%)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (12.3)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (12.9)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (19.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.407</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Biological parameters</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Urinary NTx/Creatinine (mmol/l)</td><td align="left" valign="top" rowspan="1" colspan="1">51.0 (29.8)</td><td align="left" valign="top" rowspan="1" colspan="1">50.0 (21.8)</td><td align="left" valign="top" rowspan="1" colspan="1">47.0 (41.0)</td><td align="left" valign="top" rowspan="1" colspan="1">56.5 (31.5)</td><td align="left" valign="top" rowspan="1" colspan="1">48.0 (27.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.432</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Urinary DPYD/Creatinine (mmol/l)</td><td align="left" valign="top" rowspan="1" colspan="1">8.9 (2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">9.3 (2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">8.8 (2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">8.9 (3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">8.5 (3.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.797</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;S-BAP (&#x003bc;g/l)</td><td align="left" valign="top" rowspan="1" colspan="1">15.0 (7.1)</td><td align="left" valign="top" rowspan="1" colspan="1">15.1 (11.0)</td><td align="left" valign="top" rowspan="1" colspan="1">15.2 (5.7)</td><td align="left" valign="top" rowspan="1" colspan="1">15.5 (9.9)</td><td align="left" valign="top" rowspan="1" colspan="1">12.2 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.069</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;S-osteocalcin (ng/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">15.2 (7.2)</td><td align="left" valign="top" rowspan="1" colspan="1">13.1 (7.4)</td><td align="left" valign="top" rowspan="1" colspan="1">16.0 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">15.5 (8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">14.5 (8.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.196</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;S-GLU (ng/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">4.2 (3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4.4 (3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3.9 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">3.4 (3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.216</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;S-GLA (ng/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">21.2 (11.4)</td><td align="left" valign="top" rowspan="1" colspan="1">19.0 (11.3)</td><td align="left" valign="top" rowspan="1" colspan="1">18.1 (10.6)</td><td align="left" valign="top" rowspan="1" colspan="1">25.0 (13.0)</td><td align="left" valign="top" rowspan="1" colspan="1">21.7 (12.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.140</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;GLU/GLA ratio</td><td align="left" valign="top" rowspan="1" colspan="1">0.206 (0.16)</td><td align="left" valign="top" rowspan="1" colspan="1">0.19 (0.13)</td><td align="left" valign="top" rowspan="1" colspan="1">0.27 (0.30)</td><td align="left" valign="top" rowspan="1" colspan="1">0.22 (0.17)</td><td align="left" valign="top" rowspan="1" colspan="1">0.17 (0.14)</td><td align="left" valign="top" rowspan="1" colspan="1">0.251</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;S-25(OH)D (nmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">75.4 (30.5)</td><td align="left" valign="top" rowspan="1" colspan="1">77.1 (36.6)</td><td align="left" valign="top" rowspan="1" colspan="1">74.2 (32.5)</td><td align="left" valign="top" rowspan="1" colspan="1">74.4 (33.1)</td><td align="left" valign="top" rowspan="1" colspan="1">74.4 (29.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.916</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;S-PTH (pmol/l)</td><td align="left" valign="top" rowspan="1" colspan="1">3.6 (2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 (2.4)</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (1.7)</td><td align="left" valign="top" rowspan="1" colspan="1">3.8 (1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.682</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;S-Creatinine (mmol/l)</td><td align="left" valign="top" rowspan="1" colspan="1">5.9 (5.8)</td><td align="left" valign="top" rowspan="1" colspan="1">5.9 (4.8)</td><td align="left" valign="top" rowspan="1" colspan="1">6.7 (6.6)</td><td align="left" valign="top" rowspan="1" colspan="1">5.2 (5.9)</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 (6.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.564</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;n-3 EPA (mg/g RBC)</td><td align="left" valign="top" rowspan="1" colspan="1">0.030 (0.030)</td><td align="left" valign="top" rowspan="1" colspan="1">0.035 (0.023)</td><td align="left" valign="top" rowspan="1" colspan="1">0.030 (0.020)</td><td align="left" valign="top" rowspan="1" colspan="1">0.040 (0.015)</td><td align="left" valign="top" rowspan="1" colspan="1">0.030 (0.030)</td><td align="left" valign="top" rowspan="1" colspan="1">0.497</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;n-3 DHA (mg/g RBC)</td><td align="left" valign="top" rowspan="1" colspan="1">0.105 (0.030)</td><td align="left" valign="top" rowspan="1" colspan="1">0.110 (0.040)</td><td align="left" valign="top" rowspan="1" colspan="1">0.100 (0.040)</td><td align="left" valign="top" rowspan="1" colspan="1">0.110 (0.033)</td><td align="left" valign="top" rowspan="1" colspan="1">0.100 (0.030)</td><td align="left" valign="top" rowspan="1" colspan="1">0.111</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Omega-3 index<xref rid="tfn_006" ref-type="table-fn"><sup>f</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">7.99 (2.59)</td><td align="left" valign="top" rowspan="1" colspan="1">8.01 (3.21)</td><td align="left" valign="top" rowspan="1" colspan="1">8.03 (2.21)</td><td align="left" valign="top" rowspan="1" colspan="1">8.01 (2.60)</td><td align="left" valign="top" rowspan="1" colspan="1">7.94 (2.80)</td><td align="left" valign="top" rowspan="1" colspan="1">0.718</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">DXA-measurements</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total body BMD (g/cm<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">1.06 (0.11)</td><td align="left" valign="top" rowspan="1" colspan="1">1.06 (0.11)</td><td align="left" valign="top" rowspan="1" colspan="1">1.05 (0.10)</td><td align="left" valign="top" rowspan="1" colspan="1">1.05 (0.15)</td><td align="left" valign="top" rowspan="1" colspan="1">1.05 (0.09)</td><td align="left" valign="top" rowspan="1" colspan="1">0.947</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total body fat mass (%)</td><td align="left" valign="top" rowspan="1" colspan="1">35.2 (8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">35.2 (8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">36.4 (5.6)</td><td align="left" valign="top" rowspan="1" colspan="1">33.3 (7.3)</td><td align="left" valign="top" rowspan="1" colspan="1">33.8 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.433</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total body fat mass (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">23.7 (8.9)</td><td align="left" valign="top" rowspan="1" colspan="1">23.6 (11.4)</td><td align="left" valign="top" rowspan="1" colspan="1">25.7 (8.2)</td><td align="left" valign="top" rowspan="1" colspan="1">22.9 (9.4)</td><td align="left" valign="top" rowspan="1" colspan="1">22.3 (7.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.576</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total body lean mass (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">44.1 (5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">44.1 (5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">43.9 (7.4)</td><td align="left" valign="top" rowspan="1" colspan="1">44.9 (6.2)</td><td align="left" valign="top" rowspan="1" colspan="1">43.1 (7.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.567</td></tr><tr><td colspan="7" align="left" valign="top" rowspan="1">Daily dietary intake</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total energy (KJ)</td><td align="left" valign="top" rowspan="1" colspan="1">8666 (3631)</td><td align="left" valign="top" rowspan="1" colspan="1">9288 (3158)</td><td align="left" valign="top" rowspan="1" colspan="1">8282 (2945)</td><td align="left" valign="top" rowspan="1" colspan="1">8628 (2819)</td><td align="left" valign="top" rowspan="1" colspan="1">8739 (3523)</td><td align="left" valign="top" rowspan="1" colspan="1">0.537</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Protein (g)</td><td align="left" valign="top" rowspan="1" colspan="1">92.1 (36.5)</td><td align="left" valign="top" rowspan="1" colspan="1">96.6 (34.0)</td><td align="left" valign="top" rowspan="1" colspan="1">90.4 (24.1)</td><td align="left" valign="top" rowspan="1" colspan="1">92.4 (39.9)</td><td align="left" valign="top" rowspan="1" colspan="1">89.2 (31.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.742</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Carbohydrate (g)</td><td align="left" valign="top" rowspan="1" colspan="1">228.3 (99.6)</td><td align="left" valign="top" rowspan="1" colspan="1">256.4 (85.9)</td><td align="left" valign="top" rowspan="1" colspan="1">216.9 (78.3)</td><td align="left" valign="top" rowspan="1" colspan="1">221.6 (96.2)</td><td align="left" valign="top" rowspan="1" colspan="1">233.6 (117.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.440</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total fat (g)</td><td align="left" valign="top" rowspan="1" colspan="1">78.5 (41.5)</td><td align="left" valign="top" rowspan="1" colspan="1">82.2 (51.7)</td><td align="left" valign="top" rowspan="1" colspan="1">75.5 (39.1)</td><td align="left" valign="top" rowspan="1" colspan="1">78.1 (32.2)</td><td align="left" valign="top" rowspan="1" colspan="1">81.1 (42.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.549</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Saturated fat (g)</td><td align="left" valign="top" rowspan="1" colspan="1">27.1 (15.4)</td><td align="left" valign="top" rowspan="1" colspan="1">27.3 (13.9)</td><td align="left" valign="top" rowspan="1" colspan="1">24.6 (12.8)</td><td align="left" valign="top" rowspan="1" colspan="1">27.9 (14.1)</td><td align="left" valign="top" rowspan="1" colspan="1">27.5 (17.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.312</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Monounsaturated fat (g)</td><td align="left" valign="top" rowspan="1" colspan="1">26.8 (14.4)</td><td align="left" valign="top" rowspan="1" colspan="1">27.7 (17.6)</td><td align="left" valign="top" rowspan="1" colspan="1">26.0 (15.5)</td><td align="left" valign="top" rowspan="1" colspan="1">26.6 (14.7)</td><td align="left" valign="top" rowspan="1" colspan="1">27.4 (13.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.649</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Polyunsaturated fat (g)</td><td align="left" valign="top" rowspan="1" colspan="1">15.5 (8.4)</td><td align="left" valign="top" rowspan="1" colspan="1">16.3 (8.6)</td><td align="left" valign="top" rowspan="1" colspan="1">15.4 (8.7)</td><td align="left" valign="top" rowspan="1" colspan="1">14.6 (9.2)</td><td align="left" valign="top" rowspan="1" colspan="1">15.7 (8.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.770</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total Vitamin D (&#x003bc;g)</td><td align="left" valign="top" rowspan="1" colspan="1">9.0 (10.9)</td><td align="left" valign="top" rowspan="1" colspan="1">8.4 (8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">8.6 (8.4)</td><td align="left" valign="top" rowspan="1" colspan="1">11.9 (13.9)</td><td align="left" valign="top" rowspan="1" colspan="1">9.0 (16.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.804</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Vitamin D from food (&#x003bc;g)</td><td align="left" valign="top" rowspan="1" colspan="1">5.8 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6.4 (4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6.3 (3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">5.0 (3.8)</td><td align="left" valign="top" rowspan="1" colspan="1">5.8 (4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.393</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total Ca (mg)</td><td align="left" valign="top" rowspan="1" colspan="1">974.5 (610.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1153.0 (595.0)</td><td align="left" valign="top" rowspan="1" colspan="1">862.0 (575.0)</td><td align="left" valign="top" rowspan="1" colspan="1">991.0 (667.0)</td><td align="left" valign="top" rowspan="1" colspan="1">913.0 (685.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Ca from food (mg)</td><td align="left" valign="top" rowspan="1" colspan="1">934.5 (552.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1066.0 (628.0)</td><td align="left" valign="top" rowspan="1" colspan="1">862.0 (415.0)</td><td align="left" valign="top" rowspan="1" colspan="1">979.0 (513.5)</td><td align="left" valign="top" rowspan="1" colspan="1">913.0 (685.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.619</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Seafood as dinner (weekly)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1.5 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.553</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Seafood as spread (weekly)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5 (1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.760</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Fish oil supplements (weekly)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (0.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (0.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (0.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0 (7.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.369</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: 25(OH)D, 25-hyroxyvitamin D; BAP, bone alkaline phosphatase; BMC, bone mineral content; BMD, bone mineral density; BMI, body mass index; Ca, calcium; DPYD, deoxypyridinoline; DXA, dual X-ray absorptiometry; n-3 EPA+DHA, omega-3 eicosapentaenoic acids+docosahexaenoic acids; GLA, carboxylated osteocalcin; GLU, undercarboxylated osteocalcin; N, numbers; NTx, telopeptides; IQR, interquartile range; PTH, parathyroid hormone; RBC, red blood cells; s, serum.</p><fn id="tfn_001"><label>a</label><p>Tablets, intervention with vitamin D and calcium tablets;</p></fn><fn id="tfn_002"><label>b</label><p>HD/HK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>;</p></fn><fn id="tfn_003"><label>c</label><p>LD/HK, intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>;</p></fn><fn id="tfn_004"><label>d</label><p>HD/LK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>.</p></fn><fn id="tfn_005"><label>e</label><p>P-value are given with one way analysis of variance between the intervention groups for normal disturbed variables and Kruskal-Wallis test for skewed disturbed variables (PTH, BMI, energy intake, and all other kinds of dietary intake), and Chi-square test for the categorical variable current smoking.</p></fn><fn id="tfn_006"><label>f</label><p>Sum %EPA + %DHA (% of sum of total fatty acids).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2_3"><title>Pre- to post-intervention results</title><sec id="s2_4"><title>Bone biomarkers</title><p>The bone resorption biomarker urinary NTx decreased within all groups, except from within the low D<sub>3</sub> + high K1 (LD/HK) group, but no significant group differences were observed (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F2">2a</xref>). Urinary DPYD was unchanged within and between all groups (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F2">2b</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Changes in urinary and serum concentrations of bone turnover markers, vitamin D and fatty acids status during the intervention. Data are given as mean (SD)</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="3" align="center" valign="top" rowspan="1">Tablets<xref rid="tfn_007" ref-type="table-fn"><sup>a</sup></xref><break/>(n=30)</th><th colspan="3" align="center" valign="top" rowspan="1">HD/HK<xref rid="tfn_008" ref-type="table-fn"><sup>b</sup></xref><break/>(n=31)</th><th colspan="3" align="center" valign="top" rowspan="1">LD/HK<xref rid="tfn_009" ref-type="table-fn"><sup>c</sup></xref><break/>(n=30)</th><th colspan="3" align="center" valign="top" rowspan="1">HD/LK<xref rid="tfn_010" ref-type="table-fn"><sup>d</sup></xref><break/>(n=31)</th><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Post</th><th align="left" valign="top" rowspan="1" colspan="1">Delta<xref rid="tfn_011" ref-type="table-fn"><sup>e</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_012" ref-type="table-fn"><sup>f</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1">Post</th><th align="left" valign="top" rowspan="1" colspan="1">Delta<xref rid="tfn_011" ref-type="table-fn"><sup>e</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_012" ref-type="table-fn"><sup>f</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1">Post</th><th align="left" valign="top" rowspan="1" colspan="1">Delta<xref rid="tfn_011" ref-type="table-fn"><sup>e</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_012" ref-type="table-fn"><sup>f</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1">Post</th><th align="left" valign="top" rowspan="1" colspan="1">Delta<xref rid="tfn_011" ref-type="table-fn"><sup>e</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_012" ref-type="table-fn"><sup>f</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_013" ref-type="table-fn"><sup>g</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_014" ref-type="table-fn"><sup>h</sup></xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">NTx/<break/>Creatinine (mmol/l)</td><td align="left" valign="top" rowspan="1" colspan="1">47.6<break/>(34.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;13.2<break/>(27.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.015</td><td align="left" valign="top" rowspan="1" colspan="1">43.4<break/>(17.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;15.8<break/>(21.7)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">53.5 (28.1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;6.2<break/>(22.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.141</td><td align="left" valign="top" rowspan="1" colspan="1">40.8<break/>(11.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;11.7<break/>(22.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.413</td><td align="left" valign="top" rowspan="1" colspan="1">0.073</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DPYD/<break/>Creatinine (mmol/l)</td><td align="left" valign="top" rowspan="1" colspan="1">8.3<break/>(1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.0<break/>(2.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.069</td><td align="left" valign="top" rowspan="1" colspan="1">8.4<break/>(1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5<break/>(3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.394</td><td align="left" valign="top" rowspan="1" colspan="1">8.1<break/>(2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5<break/>(3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.349</td><td align="left" valign="top" rowspan="1" colspan="1">8.2<break/>(1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.5<break/>(2.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.287</td><td align="left" valign="top" rowspan="1" colspan="1">0.890</td><td align="left" valign="top" rowspan="1" colspan="1">0.958</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Osteocalcin (ng/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">14.8 (7.1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.9<break/>(3.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.199</td><td align="left" valign="top" rowspan="1" colspan="1">14.4 (5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.9<break/>(3.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.006</td><td align="left" valign="top" rowspan="1" colspan="1">15.6 (7.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.1<break/>(5.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.038</td><td align="left" valign="top" rowspan="1" colspan="1">14.4<break/>(6.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4<break/>(4.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.598</td><td align="left" valign="top" rowspan="1" colspan="1">0.084</td><td align="left" valign="top" rowspan="1" colspan="1">0.300</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLU (ng/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">4.6<break/>(3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3<break/>(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.190</td><td align="left" valign="top" rowspan="1" colspan="1">3.6<break/>(1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.5<xref rid="tfn_015" ref-type="table-fn"><sup>i</sup></xref><break/>(2.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">4.4<break/>(2.6)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.7<break/>(1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.026</td><td align="left" valign="top" rowspan="1" colspan="1">3.6<break/>(1.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.2<break/>(1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.477</td><td align="left" valign="top" rowspan="1" colspan="1">0.015</td><td align="left" valign="top" rowspan="1" colspan="1">0.024</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLA (ng/ml)</td><td align="left" valign="top" rowspan="1" colspan="1">18.8 (4.4)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.0<break/>(7.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.043</td><td align="left" valign="top" rowspan="1" colspan="1">19.5<break/>(5.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.5<break/>(7.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.721</td><td align="left" valign="top" rowspan="1" colspan="1">21.6 (6.3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.3<break/>(6.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.076</td><td align="left" valign="top" rowspan="1" colspan="1">18.1<break/>(6.1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;4.1<xref rid="tfn_016" ref-type="table-fn"><sup>j</sup></xref><break/>(6.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.070</td><td align="left" valign="top" rowspan="1" colspan="1">0.050</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GLU/GLA ratio</td><td align="left" valign="top" rowspan="1" colspan="1">0.26 (0.23)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.03<break/>(0.22)</td><td align="left" valign="top" rowspan="1" colspan="1">0.510</td><td align="left" valign="top" rowspan="1" colspan="1">0.19 (0.07)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.14<xref rid="tfn_017" ref-type="table-fn"><sup>k</sup></xref><break/>(0.21)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.21 (0.10)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.02<break/>(0.12)</td><td align="left" valign="top" rowspan="1" colspan="1">0.279</td><td align="left" valign="top" rowspan="1" colspan="1">0.21<break/>(0.13)</td><td align="left" valign="top" rowspan="1" colspan="1">0.01<break/>(0.14)</td><td align="left" valign="top" rowspan="1" colspan="1">0.643</td><td align="left" valign="top" rowspan="1" colspan="1">0.010</td><td align="left" valign="top" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BAP (&#x003bc;g/l)</td><td align="left" valign="top" rowspan="1" colspan="1">15.7<break/>(9.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.6<break/>(5.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.103</td><td align="left" valign="top" rowspan="1" colspan="1">15.4<break/>(4.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.2<break/>(3.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.756</td><td align="left" valign="top" rowspan="1" colspan="1">17.3 (8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.2<break/>(4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.108</td><td align="left" valign="top" rowspan="1" colspan="1">13.4 (5.3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.7<break/>(4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.347</td><td align="left" valign="top" rowspan="1" colspan="1">0.374</td><td align="left" valign="top" rowspan="1" colspan="1">0.556</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">25(OH)D (nmol/l)</td><td align="left" valign="top" rowspan="1" colspan="1">85.4<break/>(20.8)</td><td align="left" valign="top" rowspan="1" colspan="1">13.7<break/>(17.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">84.0<break/>(15.6)</td><td align="left" valign="top" rowspan="1" colspan="1">11.4<break/>(16.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">69.7<break/>(18.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.2<xref rid="tfn_018" ref-type="table-fn"><sup>l</sup></xref><break/>(12.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.590</td><td align="left" valign="top" rowspan="1" colspan="1">86.8<break/>(18.1)</td><td align="left" valign="top" rowspan="1" colspan="1">12.1<break/>(16.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EPA (mg/g)</td><td align="left" valign="top" rowspan="1" colspan="1">0.03<break/>(0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.01<xref rid="tfn_019" ref-type="table-fn"><sup>m</sup></xref><break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.05<break/>(0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">0.02<break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.05<break/>(0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">0.01<break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">0.038</td><td align="left" valign="top" rowspan="1" colspan="1">0.05<break/>(0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">0.01<break/>(0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DHA (mg/g)</td><td align="left" valign="top" rowspan="1" colspan="1">0.09<break/>(0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.02<xref rid="tfn_020" ref-type="table-fn"><sup>n</sup></xref><break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">0.11<break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">0.00<break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">0.511</td><td align="left" valign="top" rowspan="1" colspan="1">0.10<break/>(0.01)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.01<break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">0.026</td><td align="left" valign="top" rowspan="1" colspan="1">0.09<break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">0.00<break/>(0.02)</td><td align="left" valign="top" rowspan="1" colspan="1">0.205</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Omega-3 index<xref rid="tfn_021" ref-type="table-fn"><sup>t</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">6.0<break/>(1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;2.2<xref rid="tfn_019" ref-type="table-fn"><sup>m</sup></xref><break/>(1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">7.6<break/>(1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.7<break/>(1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.056</td><td align="left" valign="top" rowspan="1" colspan="1">7.7<break/>(1.1)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.2<break/>(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.505</td><td align="left" valign="top" rowspan="1" colspan="1">7.5<break/>(1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3<break/>(1.6)</td><td align="left" valign="top" rowspan="1" colspan="1">0.362</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: 25(OH)D, 25-hyroxyvitamin D in serum (S); BAP, bone alkaline phosphatase in s; DHA, omega-3 docosahexaenoic acids in red blood cells (RBC); DPYD, deoxypyridinoline in urin; EPA, omega-3 eicosapentaenoic acids in RBC; GLA, carboxylated osteocalcin; GLU, undercarboxylated osteocalcin; N, numbers; NTx, telopeptides in urin; SD, standard deviation.</p><fn id="tfn_007"><label>a</label><p>Tablets, intervention with vitamin D and calcium tablets;</p></fn><fn id="tfn_008"><label>b</label><p>HD/HK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>;</p></fn><fn id="tfn_009"><label>c</label><p>LD/HK, intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>;</p></fn><fn id="tfn_010"><label>d</label><p>HD/LK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>.</p></fn><fn id="tfn_011"><label>e</label><p>Mean (SD) unadjusted changes during intervention.</p></fn><fn id="tfn_012"><label>f</label><p>P-value are given with Paired-samples t-test for comparison of individual pre- and post-intervention values.</p></fn><fn id="tfn_013"><label>g</label><p>P-value are given with unadjusted General linear model.</p></fn><fn id="tfn_014"><label>h</label><p>P-value are given with General linear model adjusted for the current pre-variable. Pairwise comparisons in General linear models with Bonferroni correction shows:</p></fn><fn id="tfn_015"><label>i</label><p>p&#x0003c;0.01 for individual group comparison with the Tablets and HD/LK groups in unadjusted and adjusted analyses.</p></fn><fn id="tfn_016"><label>j</label><p>p&#x0003c;0.05 for individual group comparison with the HD/HK and LD/HK group in adjusted analyses.</p></fn><fn id="tfn_017"><label>k</label><p>p&#x0003c;0.05 for individual group comparison with the Tablets, LD/HK and HD/LK groups in unadjusted and adjusted analyses.</p></fn><fn id="tfn_018"><label>l</label><p>p&#x0003c;0.001 for individual group comparison with the Tablets, HD/HK, and HD/LK groups in unadjusted and adjusted analyses.</p></fn><fn id="tfn_019"><label>m</label><p>p&#x0003c;0.001 for individual group comparison with the HD/HK, LD/HK and HD/LK groups in unadjusted and adjusted analyses.</p></fn><fn id="tfn_020"><label>n</label><p>p&#x0003c;0.05 for individual group comparison with the HD/HK, LD/HK and HD/LK groups in unadjusted and adjusted analyses.</p></fn><fn id="tfn_021"><label>t</label><p>The content of EPA and DHA in RBC membranes expressed as percent of total fatty acids.</p></fn></table-wrap-foot></table-wrap><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>a, and b</title><p>Pre-and post-intervention results of the bone resorption biomarker urinary N-telopeptides (NTx) (Figure <xref ref-type="fig" rid="F2">2a</xref>) and urinary deoxypyridinoline/creatinine (DPYD) (Figure <xref ref-type="fig" rid="F2">2b</xref>) within each intervention group. The horizontal line through the box represents the median. The lower boundary of the box is the 25<sup>th</sup> percentile and the upper bounder is the 75<sup>th</sup> percentile. The smallest and largest observed values within the distribution are represented by the horizontal at either end of the box. Tablets (n=30), intervention with vitamin D and calcium tablets; HD/HK (n=31), intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>; LD/HK (n=30), intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>; HD/LK (n=31), intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>. P between the groups for urinary NTx = 0.413 and urinary DPYD = 0.890.</p></caption><graphic xlink:href="oncotarget-07-69200-g002"/></fig><p>The bone matrix protein biomarker s-osteocalcin decreased within the HD/HK and LD/HK groups, but there were no differences between the groups (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F3">3a</xref>). s-GLU decreased within the HD/HK and LD/HK groups, and significant differences between the groups were found with better outcome in the HD/HK group than the tablet (p=0.004), LD/HK (p=0.035) and high D<sub>3</sub> + low K1 (HD/LK) groups (p=0.020). The vitamin K dependent s-GLA decreased within the tablet and HD/LK groups, and the outcome was better in the HD/LK group than the HD/HK (p=0.033) and LD/HK (p=0.018) groups (Table <xref ref-type="table" rid="T2">2</xref>). GLU/GLA ratio decreased within the HD/HK group and differences showed better results in the HD/HK group compared to the tablet (p=0.001), LD/HK (p=0.025) and HD/LK (p=0.003) groups (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F3">3b</xref>). S-BAP did not change within or between any of the groups from pre- to post-intervention (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F3">3c</xref>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>a, b, and c</title><p>Pre-and post-intervention results of the bone formation biomarker serum (s)-osteocalcin (Figure <xref ref-type="fig" rid="F3">3a</xref>), the GLU/GLA ratio (Figure <xref ref-type="fig" rid="F3">3b</xref>), and s-one alkaline phosphatase (s-BAP) (Figure <xref ref-type="fig" rid="F3">3c</xref>) within each intervention group. The horizontal line through the box represents the median. The lower boundary of the box is the 25<sup>th</sup> percentile and the upper bounder is the 75<sup>th</sup> percentile. The smallest and largest observed values within the distribution are represented by the horizontal at either end of the box. Tablets (n=30), intervention with vitamin D and calcium tablets; HD/HK (n=31), intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>; LD/HK (n=30), intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>; HD/LK (n=31), intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>. P between the groups for s-osteocalcin = 0.084, for GLU/GLA ratio = 0.010, and for s-BAP = 0.374.</p></caption><graphic xlink:href="oncotarget-07-69200-g003"/></fig></sec></sec><sec id="s2_5"><title>Nutritional status</title><p>S-25(OH)D increased within all groups, except from in the LD/HK group from pre- to post-intervention, and the group differences were large (p&#x0003c;0.001) (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F4">4a</xref>). EPA increased within all groups, except from in the tablet group, where decreased levels were found (p between the tablet and the other groups &#x0003c;0.001) (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F4">4b</xref>). DHA decreased within the tablet and LD/HK groups, and was unchanged within the other groups, and significant differences between the groups were observed with better status in the HD/HK (p&#x0003c;0.001), LD/HK (p=0.032) and HD/LK groups (p=0.001) than in the tablet group (Table <xref ref-type="table" rid="T2">2</xref>, Figure <xref ref-type="fig" rid="F4">4c</xref>). Furthermore, the omega-3 index decreased within the tablet group, whereas the results were unchanged in the other groups (p&#x0003c;0.001) (Table <xref ref-type="table" rid="T2">2</xref>).</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>a, b and c</title><p>Pre-and post-intervention results of serum 25-hydroxyvitamin D (s-25(OH)D) (Figure <xref ref-type="fig" rid="F4">4a</xref>), eicosapentaenoic acid (EPA) (Figure <xref ref-type="fig" rid="F4">4b</xref>) and docosahexaenoic acid (DHA) (Figure <xref ref-type="fig" rid="F4">4c</xref>) within each intervention group. The horizontal line through the box represents the median. The lower boundary of the box is the 25<sup>th</sup> percentile and the upper bounder is the 75<sup>th</sup> percentile. The smallest and largest observed values within the distribution are represented by the horizontal at either end of the box. Tablets (n=30), intervention with vitamin D and calcium tablets; HD/HK (n=31), intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>; LD/HK (n=30), intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>; HD/LK (n=31), intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>. P between the groups for s-25(OH)D = 0.001, EPA &#x0003c;0.001, and DHA = 0.001.</p></caption><graphic xlink:href="oncotarget-07-69200-g004"/></fig></sec><sec id="s2_6"><title>Total fat mass and lean mass</title><p>Total body fat mass (%) decreased and total lean mass (kg) increased within the HD/HK group from pre- to post-intervention, but no significant differences between the groups were observed (Table <xref ref-type="table" rid="T3">3</xref>). Total body BMD was also investigated but no significant difference within or between the intervention groups were observed (data not shown).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Changes in body composition during the intervention. Data are given as mean (SD)</title></caption><table frame="box" rules="all"><thead><tr><th rowspan="2" align="left" valign="top" colspan="1"/><th colspan="3" align="center" valign="top" rowspan="1">Tablets<xref rid="tfn_022" ref-type="table-fn"><sup>a</sup></xref><break/>(n=30)</th><th colspan="3" align="center" valign="top" rowspan="1">HD/HK<xref rid="tfn_023" ref-type="table-fn"><sup>b</sup></xref><break/>(n=31)</th><th colspan="3" align="center" valign="top" rowspan="1">LD/HK<xref rid="tfn_024" ref-type="table-fn"><sup>c</sup></xref><break/>(n=30)</th><th colspan="3" align="center" valign="top" rowspan="1">HD/LK<xref rid="tfn_025" ref-type="table-fn"><sup>d</sup></xref><break/>(n=31)</th><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Post</th><th align="left" valign="top" rowspan="1" colspan="1">Delta<xref rid="tfn_026" ref-type="table-fn"><sup>e</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_027" ref-type="table-fn"><sup>f</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1">Post</th><th align="left" valign="top" rowspan="1" colspan="1">Delta<xref rid="tfn_026" ref-type="table-fn"><sup>e</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_027" ref-type="table-fn"><sup>f</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1">Post</th><th align="left" valign="top" rowspan="1" colspan="1">Delta<xref rid="tfn_026" ref-type="table-fn"><sup>e</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_027" ref-type="table-fn"><sup>f</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1">Post</th><th align="left" valign="top" rowspan="1" colspan="1">Delta<xref rid="tfn_026" ref-type="table-fn"><sup>e</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_027" ref-type="table-fn"><sup>f</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>p</italic>-value<xref rid="tfn_028" ref-type="table-fn"><sup>g</sup></xref></th><th align="left" valign="top" rowspan="1" colspan="1"><italic>P</italic>-value<xref rid="tfn_029" ref-type="table-fn"><sup>h</sup></xref></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Total body fat mass (%)<xref rid="tfn_032" ref-type="table-fn"><sup>k</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">34.2 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.3<break/>(1.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.115</td><td align="left" valign="top" rowspan="1" colspan="1">34.5 (5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.9<xref rid="tfn_030" ref-type="table-fn"><sup>i</sup></xref><break/>(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">33.2 (4.9)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.6<break/>(1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.099</td><td align="left" valign="top" rowspan="1" colspan="1">33.2 (5.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.1<break/>(1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.605</td><td align="left" valign="top" rowspan="1" colspan="1">0.141</td><td align="left" valign="top" rowspan="1" colspan="1">0.184</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total body fat mass (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">24.8<break/>(8.5)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.1<break/>(4.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0.600</td><td align="left" valign="top" rowspan="1" colspan="1">25.8<break/>(8.0)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.4<break/>(1.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.181</td><td align="left" valign="top" rowspan="1" colspan="1">23.8 (6.6)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.4<break/>(1.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0.297</td><td align="left" valign="top" rowspan="1" colspan="1">23.6 (7.5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.0<break/>(1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.752</td><td align="left" valign="top" rowspan="1" colspan="1">0.421</td><td align="left" valign="top" rowspan="1" colspan="1">0.664</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Total body lean mass (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">43.7 (4.4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.3<break/>(1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.087</td><td align="left" valign="top" rowspan="1" colspan="1">45.4 (5.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1.0<sub>j</sub><break/>(1.3)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">44.8 (4.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0.6<break/>(5.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.575</td><td align="left" valign="top" rowspan="1" colspan="1">44.4 (6.1)</td><td align="left" valign="top" rowspan="1" colspan="1">0.4<break/>(1.0)</td><td align="left" valign="top" rowspan="1" colspan="1">0.059</td><td align="left" valign="top" rowspan="1" colspan="1">0.196</td><td align="left" valign="top" rowspan="1" colspan="1">0.244</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: SD, standard deviation.</p><fn id="tfn_022"><label>a</label><p>Tablets, intervention with vitamin D and calcium tablets;</p></fn><fn id="tfn_023"><label>b</label><p>HD/HK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>;</p></fn><fn id="tfn_024"><label>c</label><p>LD/HK, intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>;</p></fn><fn id="tfn_025"><label>d</label><p>HD/LK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>.</p></fn><fn id="tfn_026"><label>e</label><p>Mean (SD) unadjusted changes during intervention.</p></fn><fn id="tfn_027"><label>f</label><p>P-value are given with Paired-samples t-test for comparison of individual pre- and post-intervention values.</p></fn><fn id="tfn_028"><label>g</label><p>P-value are given with unadjusted General linear model.</p></fn><fn id="tfn_029"><label>h</label><p>P-value are given with General linear model adjusted for the current pre-variable.</p></fn><fn id="tfn_030"><label>i</label><p>p&#x0003c;0.05 for individual group comparison with the HD/LK group in unadjusted and adjusted analyses.</p></fn><fn id="tfn_031"><label>j</label><p>p&#x0003c;0.05 for individual group comparison with the LD/HK group in unadjusted and adjusted analyses.</p></fn><fn id="tfn_032"><label>k</label><p>Total body fat mass (%) = percent of soft tissue.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2_7"><title>Other analyses</title><p>S-bile acids, hydroxybutyrat, free fatty acids, glucose, glycerol, high-density lipoprotein (HDL), low-density lipoprotein (LDL) and total cholesterol, lactate, and triglycerides were also analyzed, but no significant differences within or between the groups from pre- to post-intervention were detected (data not shown).</p></sec><sec id="s2_8"><title>Eta squared calculations</title><p>Eta squared calculations for the analyses performed within the intervention groups as shown in Table <xref ref-type="table" rid="T2">2</xref> and <xref ref-type="table" rid="T3">3</xref>, showed strong effect size [<xref rid="R5" ref-type="bibr">5</xref>] for all significant results from pre- to post-intervention (Eta squared &#x0003e;0.15).</p></sec><sec id="s2_9"><title>Compliance</title><p>In the tablet group, 90% of the women had less than seven missing days of supplements during the whole intervention (Table <xref ref-type="table" rid="T4">4</xref>). In all salmon groups,92.4% of the participants reported that they had less than two missing study meals (Table <xref ref-type="table" rid="T4">4</xref>). Thus, the compliance in all intervention groups was similar on the weekly basis.</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Reported compliance (missing days) of study meals and supplements in the different intervention groups. Data are given as numbers (%)</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Tablets<xref rid="tfn_033" ref-type="table-fn"><sup>a</sup></xref><break/>(n=30)</th><th align="left" valign="top" rowspan="1" colspan="1">HD/HK<xref rid="tfn_034" ref-type="table-fn"><sup>b</sup></xref><break/>(n=31)</th><th align="left" valign="top" rowspan="1" colspan="1">LD/HK<xref rid="tfn_035" ref-type="table-fn"><sup>c</sup></xref><break/>(n=30)</th><th align="left" valign="top" rowspan="1" colspan="1">HD/LK<xref rid="tfn_036" ref-type="table-fn"><sup>d</sup></xref><break/>(n=31)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Calcigran (Nycoplus + Forte)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No days</td><td align="left" valign="top" rowspan="1" colspan="1">11 (36.7)</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1-3 days</td><td align="left" valign="top" rowspan="1" colspan="1">13 (43.3)</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;4-7 days</td><td align="left" valign="top" rowspan="1" colspan="1">3 (10)</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;8-10 days</td><td align="left" valign="top" rowspan="1" colspan="1">3 (10)</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Study meals (salmon)<xref rid="tfn_037" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No days</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">26 (83.9)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (80)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (71)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1-2 days</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">3 (9.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (25.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;3-5 days</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (13.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Calcium (Weifa)<xref rid="tfn_037" ref-type="table-fn"><sup>e</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No days</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">16 (51.6)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (33.3)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (45.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;1-3 days</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">7 (22.6)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (23.3)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (32.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;4-7 days</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">6 (19.4)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (23.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (16.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;8-10 days</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;11-14 days</td><td align="left" valign="top" rowspan="1" colspan="1">-</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.2)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.5)</td></tr></tbody></table><table-wrap-foot><fn id="tfn_033"><label>a</label><p>Tablets, intervention with vitamin D and calcium tablets;</p></fn><fn id="tfn_034"><label>b</label><p>HD/HK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>;</p></fn><fn id="tfn_035"><label>c</label><p>LD/HK, intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>;</p></fn><fn id="tfn_036"><label>d</label><p>HD/LK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>.</p></fn><fn id="tfn_037"><label>e</label><p>Chi-square test for comparison between the salmon groups separately for study meals and calcium showed p&#x0003e;0.05.</p></fn></table-wrap-foot></table-wrap><p>In addition, 100% of the participants in the HD/HK group, 96.7% in the LD/HK group and 90.3% in the HD/LK group consumed always the whole portion of salmon in every study meal. Four participants (one in the LD/HK group and three in the HD/LK group) consumed usually the whole portion of salmon. There was no significant differences between the groups (p&#x0003c;0.05).</p></sec><sec id="s2_10"><title>Dietary patterns</title><p>Ten (8.2%) of the participants reported changes due to dietary patterns, other than the intervention itself. Reasons for this were as following: four (one in each of the four intervention groups) reported that they started on a diet to reduce weight, three (one in each of the salmon groups) reduced intake of sweets, two (one in the LD/HK group and one in the HD/LK group) reported reduced intake of bread. In addition, one woman in the HD/HK group started on iron supplements. No significant differences between the groups were observed (p&#x0003e;0.05).</p><p>During the intervention, 60% of the women in the tablet group ate lean seafood &#x02265; two times the week, which was more often than the women in the HD/HK (29%), LD/HK (16.7%), and HD/LK (41.9%) groups (p=0.004).</p></sec><sec id="s2_11"><title>Side effects of Vitamin D tablets, Calcigran forte and calcium supplements</title><p>Side effects of vitamin D tablets and calcium supplements are shown in Table <xref ref-type="table" rid="T5">5</xref>. The most common side effect was stomach upsets (abdominal pain, nausea, bloating, and constipation), and 12 (38.7%) of the participants in the HD/LK group reported stomach upsets often/always. Other side effects were headache and &#x0201c;tasted bad&#x0201d; (Table <xref ref-type="table" rid="T5">5</xref>). Furthermore, two participants in the tablet group reported dry mouth often as a side effect. No participants reported side effects like tiredness. In addition, two participants (one in each of the HD/HK and HD/LK group) stopped using calcium supplements because of side effects.</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Reported side effects of vitamin D and calcium supplements. Data are given as numbers (%)</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Overall<break/>(n=122)</th><th align="left" valign="top" rowspan="1" colspan="1">Tablets<xref rid="tfn_038" ref-type="table-fn"><sup>a</sup></xref><break/>(n=30)</th><th align="left" valign="top" rowspan="1" colspan="1">HD/HK<xref rid="tfn_039" ref-type="table-fn"><sup>b</sup></xref><break/>(n=31)</th><th align="left" valign="top" rowspan="1" colspan="1">LD/HK<xref rid="tfn_040" ref-type="table-fn"><sup>c</sup></xref><break/>(n=30)</th><th align="left" valign="top" rowspan="1" colspan="1">HD/LK<xref rid="tfn_041" ref-type="table-fn"><sup>d</sup></xref><break/>(n=31)</th></tr></thead><tbody><tr><td colspan="6" align="left" valign="top" rowspan="1">Stomach upsets<xref rid="tfn_042" ref-type="table-fn"><sup>e</sup></xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Never</td><td align="left" valign="top" rowspan="1" colspan="1">53 (43.4)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (56.7)</td><td align="left" valign="top" rowspan="1" colspan="1">15 (48.4)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (53.3)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (16.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rarely</td><td align="left" valign="top" rowspan="1" colspan="1">17 (13.9)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">5 (16.1)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (20.0)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (19.4)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sometimes</td><td align="left" valign="top" rowspan="1" colspan="1">29 (23.8)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (33.3)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (29.0)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (25.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Often</td><td align="left" valign="top" rowspan="1" colspan="1">18 (14.8)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (20.0)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (25.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Always</td><td align="left" valign="top" rowspan="1" colspan="1">5 (4.1)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">4 (12.9)</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Tasted bad</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Never</td><td align="left" valign="top" rowspan="1" colspan="1">107 (87.7)</td><td align="left" valign="top" rowspan="1" colspan="1">27 (90.0)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (93.5)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (76.7)</td><td align="left" valign="top" rowspan="1" colspan="1">28 (90.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rarely</td><td align="left" valign="top" rowspan="1" colspan="1">3 (2.5)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sometimes</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Often</td><td align="left" valign="top" rowspan="1" colspan="1">4 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Always</td><td align="left" valign="top" rowspan="1" colspan="1">7 (5.7)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6.5)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (10.0)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.2)</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Headache</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Never</td><td align="left" valign="top" rowspan="1" colspan="1">121 (99.2)</td><td align="left" valign="top" rowspan="1" colspan="1">29 (96.7)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">30 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (100)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rarely</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sometimes</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Often</td><td align="left" valign="top" rowspan="1" colspan="1">1 (0.8)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.3)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Always</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table><table-wrap-foot><fn id="tfn_038"><label>a</label><p>Tablets, intervention with vitamin D and calcium tablets;</p></fn><fn id="tfn_039"><label>b</label><p>HD/HK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>;</p></fn><fn id="tfn_040"><label>c</label><p>LD/HK, intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>;</p></fn><fn id="tfn_041"><label>d</label><p>HD/LK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>.</p></fn><fn id="tfn_042"><label>e</label><p>Stomach upsets included abdominal pain, nausea, bloating, and constipation.</p></fn><fn id="tfn_043"><label>f</label><p>Chi-square test for comparison between the intervention groups separately for stomach upsets, tasted bad and headache showed p&#x0003e;0.05.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s3"><title>DISCUSSION</title><p>In the present study, Atlantic salmon fillet was successfully tailored yielding enriched levels of vitamin D and vitamin K. Earlier studies with smaller salmon (first-feeding and smolt) have also demonstrated increased levels of vitamin D in whole salmon [<xref rid="R34" ref-type="bibr">34</xref>] and salmon tissues [<xref rid="R35" ref-type="bibr">35</xref>] due to increased dietary level. However, this is the first time it has been shown in commercially sized fish.</p><p>Positive effects of intake of tailor-made Atlantic salmon on several of the investigated bone formation and resorption markers in healthy postmenopausal women were observed. Especially the HD/HK group had good outcomes on more of these parameters, including urinary NTx, s-osteocalcin, s-GLU and the GLU/GLA ratio. We might speculate if our findings are a result of a synergy effect by giving calcium, vitamin D, and K simultaneously as earlier observed in supplemental studies. Vitamin K is important for activating osteocalcin [<xref rid="R16" ref-type="bibr">16</xref>], and carboxylation of osteocalcin is a marker of vitamin K status [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. Most of the documentations of vitamin K related to bone health is based on studies with vitamin K<sub>2</sub> [<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R36" ref-type="bibr">36</xref>]. However, even though the documentations of similar effects of vitamin K<sub>1</sub> is not as strong as K<sub>2</sub>, a combination of low serum levels of vitamins K<sub>1</sub> and D have been associated with increased risk of hip fracture in elderly [<xref rid="R37" ref-type="bibr">37</xref>]. Both low levels and intakes of vitamin K<sub>1</sub> have been associated with osteoporosis [<xref rid="R19" ref-type="bibr">19</xref>&#x02013;<xref rid="R22" ref-type="bibr">22</xref>], and our findings indicate that vitamin K<sub>1</sub> has a positive effect as well.</p><p>Our participants in the different groups had adequate levels of s-25(OH)D at baseline, but levels above 75 nmol/L are recommended to maximize vitamin D's beneficial effects for health [<xref rid="R38" ref-type="bibr">38</xref>]. However, it is still not documented in randomized controlled studies if levels above 75 nmol/L can improve BMD, decrease fracture risk and bone turnover markers.</p><p>We found increased levels of s-25(OH)D in all groups from pre- to post-intervention, except in the LD/HK group, which indicate that intake of standard Atlantic salmon alone is not enough to improve vitamin D status. The content of vitamin D<sub>3</sub> in fish fillets reflects the fish feed vitamin D<sub>3</sub> content [<xref rid="R34" ref-type="bibr">34</xref>]. The salmon served in our LD/HK group contained an average of 0.09 mg vitamin D<sub>3</sub> per kg fillet, which is equivalent with data on commercial farmed salmon fillet from 2006 (0.08 mg/kg) [<xref rid="R4" ref-type="bibr">4</xref>]. However, with steadily less marine ingredients and more plant based material, vitamin D<sub>3</sub> content in fish feed has decreased further and data from 2012 show an average value of 0.06 mg/kg fillet [<xref rid="R4" ref-type="bibr">4</xref>]. In addition, the increments in vitamin D in the current study were as large in the fish groups (HD/HK and HD/LK) as in the tablet group. Even though most of the participants had sufficient vitamin D status at enrollment, two servings/week with tailor-made Atlantic salmon fed with high vitamin D<sub>3</sub> (0.35-0.38 mg/kg/fillet) further increased their vitamin D status. We did not find any difference in fish or vitamin D intake at baseline in our participants, thus the follow-up results seem to be reliable. Except for a significant higher intake of lean fish in the tablet group, there was no other differences in dietary pattern between the intervention groups. Lean fish does not contribute with vitamin D.</p><p>All groups eating salmon had increased levels of EPA from pre- to post-intervention. DHA was unchanged or even decreased in the LD/HK group. These findings can probably be explained by the fact that the amount of DHA in the fish fillet was not high enough to give any further increase. In the tablet group, the participants had decreased levels of both EPA and DHA.</p><p>Our results show that two meals/week with tailor-made salmon seems to maintain the omega-3 index; even though the DHA was relatively low in the current salmon fillet. The omega-3 index has been used to predict coronary heart disease in previous studies, and based on these findings an omega-3 index &#x02265; 8% is related to greatest protection, and &#x02264; 4% to least protection [<xref rid="R39" ref-type="bibr">39</xref>]. All our intervention groups had an omega-3 index median of approximately 8% at baseline, and the fish groups preserved this level at post-intervention, however the tablet group had a relatively large reduction, and at follow-up, the level was 5.7%. These findings shows that lean fish alone, even with a higher intake compared to the salmon groups, is not enough to keep the level of EPA and DHA in RBC.</p><p>Generally, animal studies support the favorable effect of omega-3 LC-PUFAs on bone health parameters [<xref rid="R40" ref-type="bibr">40</xref>]. In humans, few studies have been conducted, but positive effects of omega-3 LC-PUFAs primarily given as fish oil or capsules on bone biomarkers and BMD have been observed [<xref rid="R41" ref-type="bibr">41</xref>], but not in all studies [<xref rid="R42" ref-type="bibr">42</xref>]. In the Framingham Osteoporosis Study, high intake of fatty fish and particularly dark fish with high levels of omega-3 LC-PUFA was associated with protective effects on BMD as exposed over a period of four years [<xref rid="R43" ref-type="bibr">43</xref>]. However, we did not find any differences in BMD between the intervention groups, and the reason may be the relatively short intervention period.</p><p>The HD/HK group also had a small significant reduction in fat mass (%) and increased lean mass from pre- to post-intervention. Omega-3 LC-PUFAs have shown to be a useful therapeutic agent for sarcopenia [<xref rid="R44" ref-type="bibr">44</xref>], which is closely related to osteoporosis [<xref rid="R45" ref-type="bibr">45</xref>], but not relevant for the included women in this study. Anyway, the ability of the skeletal muscle to use amino acids to build constitutive proteins is gradually lost with age and this is partly due to decline in skeletal muscle insulin sensitivity. Omega-3 LC-PUFA can improve insulin-mediated glucose metabolism in insulin-resistant states [<xref rid="R46" ref-type="bibr">46</xref>]. It should also be mentioned that not only omega-3 LC-PUFAs, but also adequate vitamin D status is important when it comes to muscle strength and risk of falls, and thus fractures in elderly [<xref rid="R47" ref-type="bibr">47</xref>, <xref rid="R48" ref-type="bibr">48</xref>]. Therefore, tailor-made salmon might also be a good source in the diet for prevention of falls and fractures.</p><p>The main strengths of this study are the randomized intervention design where we had the opportunity to enrich the fish feed with different content of vitamin D<sub>3</sub> and K<sub>1</sub>. The participants in the fish groups were blinded. In addition, the compliance was good. However, our study has some limitations. The trial was performed in a relatively young, healthy sample of postmenopausal women aged 50-64 years. Reduced bone health is more common in older women, but this age span was chosen because these women are especially prone to develop osteoporosis because of estrogen decline. From a clinical point of view, it is important to search for clinical effects that can prevent osteoporosis. In the next step, hopefully this can increase quality of life and reduce the socioeconomic cost of having osteoporotic patients in hospital. Next to age and female gender, BMD is the strongest predictor of osteoporotic fractures [<xref rid="R49" ref-type="bibr">49</xref>], and femoral neck BMD is the recommended reference area for description of osteoporosis [<xref rid="R50" ref-type="bibr">50</xref>]. We had BMD measurements of total body only, but as the intervention period was relatively short, we did not expect any large changes in the participants BMD.</p><p>In conclusions, increased intake of tailor-made salmon containing high levels of vitamin D<sub>3</sub> (0.35-0.38 mg/kg/fillet), and supplements with the same weekly contribution had a positive influence on bone health as measured by bone biomarkers in postmenopausal women. Consequently, an increased level of vitamin D<sub>3</sub> at least to original level in feed for salmonids will contribute to an improved vitamin D<sub>3</sub> status and may have a positive effect on human bone health.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Ethics statement</title><p>Informed consent was obtained from all participants, and the study was approved by the Regional Committee for Research Ethics West (252.07 and 2010/605-3), and the Norwegian Social Science Data Service. The study was registered at ClinicalTrials.gov (NCT02615301).</p></sec><sec id="s4_2"><title>Sample size and power calculation</title><p>Power calculation revealed that a minimum of 30 subjects should be included in each intervention group. The calculation was based on vitamin D tablets and an estimated change of 10% from pre- to post-intervention. Strength was set to 80%. It was also taken into account a measurement uncertainty of 10% on <italic>high-performance liquid chromatography</italic> (HPLC) used to analyse vitamin D metabolites, and an assumed dropout rate of approximately 20%.</p></sec><sec id="s4_3"><title>Study population</title><p>The participants in the current randomized intervention trial were recruited through a local newspaper in Bergen, Norway in January 2009, and 147 women were interested to participate in the study (Figure <xref ref-type="fig" rid="F5">5</xref>). Of these, 20 women were excluded after telephone interview because they did not meet the inclusion criteria. Inclusion criteria comprised postmenopausal women, Caucasian ethnicity, age range 50-65 years and having postmenopausal age of at least one year. To minimize any confounding effects on bone health parameters like osteocalcin and BMD, subjects with the following conditions were excluded; osteoporotic fracture, medical treatment for osteoporosis, warfarin treatment, creatinine above or below normal range, hypervitaminosis D, malabsorption syndrome, inflammatory bowel disease, or inflammatory rheumatic diseases. In addition, women who had planned to go away on holiday during the intervention could not participate. No participants were excluded after the physical examination. The 127 (86.4%) women were individually randomized into four intervention groups: three salmon groups and one tablet group. The salmon had three different vitamin D<sub>3</sub>/vitamin K<sub>1</sub> combinations: high D<sub>3</sub> + high K<sub>1</sub> (HD/HK), low D<sub>3</sub> + high K<sub>1</sub> (LD/HK), or high D<sub>3</sub> + low K<sub>1</sub> (HD/LK). Four women did not complete the intervention period, and one woman was excluded from the analyses after the intervention because of missing blood samples. Thus, 122 (83%) women were included in the final study sample (Figure <xref ref-type="fig" rid="F5">5</xref>).</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Flow-chart showing the study population</title><p>Tablets, intervention with vitamin D and calcium tablets; HD/HK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>; LD/HK, intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>; HD/LK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1.</sub></p></caption><graphic xlink:href="oncotarget-07-69200-g005"/></fig></sec><sec id="s4_4"><title>Tailor-made Atlantic salmon</title><p>The Atlantic salmon (<italic>Salmo salar L.)</italic> was produced at GIFAS (Gildesk&#x000e5;l Research station, Inndyr, Norway). The fish were kept in net pens (5x5x5 m) in the sea and fed a dry, extruded feed for four months from an initial body weight of two kg. The feed (produced at Skretting ARC Feed Technology Plant) contained 38% crude protein and 34% crude fat, in accordance with commercial diets for this size of salmon. The dry matter of the feed was 94.6-94.8%. The feed contained three different levels of vitamin D<sub>3</sub> (cholecalciferol) and vitamin K<sub>1</sub> (phylloquinone), in three different combinations: HD/HK 2.9 and 4.3 mg/kg, respectively, LD/HK 0.23 and 4.7 mg/kg, HD/LK 2.6 and &#x0003c;0.001 mg/kg. The fish were harvested at about 4.5 kg and slaughtered at Fiskekroken AS, S&#x000f8;rarn&#x000f8;y, Norway. The fish were transported by car <italic>pre rigor,</italic> and processed into skin and boneless portions (150 g), vacuum packed, and frozen by Rex Star Seafood (Tysnes, Norway). The fish were transported frozen to National Institute of Nutrition and Seafood Research (NIFES), Bergen, Norway for storage at &#x02212;30&#x000b0;C until use.</p></sec><sec id="s4_5"><title>Experimental groups</title><p>Prior to randomization, the vitamin D status of the participants was assessed. Thereafter the randomization process was run electronically until there were no significant differences in mean vitamin D status between the four groups. The randomization was done according to procedures recommended by the Norwegian Institute of Public Health [<xref rid="R51" ref-type="bibr">51</xref>]. Researchers at NIFES did the randomization, and technicians at Center of Clinical Trials, Bergen, Norway did the enrolling and assigning of participants to the study. The participants in the fish groups were blinded to dose of vitamin D3 and K1 in their respective study group. In addition, the intervention groups were coded and researchers and technicians at NIFES were blinded until statistical analyses were done. The fish groups were provided with farmed Atlantic salmon in portions of 150 grams and hand-outs with dinner recipes. They were instructed to have salmon for dinner two times per week for a period of 12 weeks. The study was run from February to May to minimize the effect of UV exposure on vitamin D status. The control group was provided with two different types of tablets; Calcigran Forte&#x000ae; containing 400 IE vitamin D and 500 mg calcium, and Nycoplus Calcigran&#x000ae; containing 200 IE vitamin D and 500 mg calcium, and was instructed to take one tablet of each type every day during the intervention. An overview of the weekly intake of vitamin D3 and K1 in the different intervention groups are given in Table <xref ref-type="table" rid="T6">6</xref>. They were informed to avoid oily fish in the same period, but had no restrictions on lean fish. The fish groups also received calcium supplements (1000 mg/d) but without vitamin D (Weifa-Kalsium&#x000ae;). The participants registered the consumed amount of salmon and tablets in a diary. The total fat- and protein content of the salmon was 14.5 and 19.5 g per 100 grams fillet, respectively. The intake of EPA+DHA in a portion (150 g) of Atlantic salmon was 2.8 g. The levels of vitamin D<sub>3</sub> and K<sub>1</sub> in the salmon for the HD/HK group was mean 0.38 (SD 0.01) and 0.54 (0.06) mg/kg, respectively, for the LD/HK group 0.09 (0.02) and 0.58 (0.10) mg/kg, and for the HD/LK group 0.35 (0.01) and 0.03 (0.00) mg/kg (Table <xref ref-type="table" rid="T6">6</xref>).</p><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><title>Weekly intake of vitamin D<sub>3</sub> and K<sub>1</sub> in the different intervention groups</title></caption><table frame="box" rules="all"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">Vitamin D<sub>3</sub> (&#x003bc;g)</th><th align="left" valign="top" rowspan="1" colspan="1">Vitamin K<sub>1</sub> (&#x003bc;g)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Tablets<xref rid="tfn_044" ref-type="table-fn"><sup>a</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">105</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HD/HK<xref rid="tfn_045" ref-type="table-fn"><sup>b</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">114</td><td align="left" valign="top" rowspan="1" colspan="1">162</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LD/HK<xref rid="tfn_046" ref-type="table-fn"><sup>c</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="left" valign="top" rowspan="1" colspan="1">162</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HD/LK<xref rid="tfn_047" ref-type="table-fn"><sup>d</sup></xref></td><td align="left" valign="top" rowspan="1" colspan="1">105</td><td align="left" valign="top" rowspan="1" colspan="1">9.6</td></tr></tbody></table><table-wrap-foot><fn id="tfn_044"><label>a</label><p>Tablets, intervention with vitamin D and calcium tablets;</p></fn><fn id="tfn_045"><label>b</label><p>HD/HK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and K<sub>1</sub>;</p></fn><fn id="tfn_046"><label>c</label><p>LD/HK, intervention with tailor made salmon with low content of vitamin D<sub>3</sub> and high content of vitamin K<sub>1</sub>;</p></fn><fn id="tfn_047"><label>d</label><p>HD/LK, intervention with tailor made salmon with high content of vitamin D<sub>3</sub> and low content of vitamin K<sub>1</sub>.</p></fn></table-wrap-foot></table-wrap><p>The content of several undesirables substances were also determined in the Atlantic salmon. The level of mercury was 0.03 mg/kg whereas the level of dioxins and dioxin-like PCBs was 0.7 ng TEQ/kg, which are both far below the EUs upper limits of 0.5 mg/kg and 6.5 ng TEQ/kg in fish, respectively. Taking into account the amount of salmon consumed per week, the intake of dioxin and dioxin-like PCBs per week represents 21% of the tolerable weekly intake (TWI) in a person weighted 70 kg [<xref rid="R52" ref-type="bibr">52</xref>]. For persons with higher body weight, salmon will contribute with a correspondingly lower percentage of TWI.</p></sec><sec id="s4_6"><title>Pre- and post-intervention measurements</title><sec id="s4_7"><title>Analytical procedures</title><p>Venous blood samples were drawn from non-fasting participants, collected into tubes, and separated through centrifugation (10 minutes, 3000 g, 20&#x000b0;C). Red blood cells (RBC) were used for analyses of fatty acid profile, whereas serum samples were used for other parameters. Second morning urine samples were collected from each participant, and RBC, serum and urine samples were kept frozen at &#x02212;80 &#x000b0;C until analysis.</p><p>BAP (Quidel Corporation, San Diego, CA, USA), s-osteocalcin (Nordic Bioscience Diagnostics, Herlev, Denmark), s-GLU and s-GLA (ng/ml) were analysed at the Hormone Laboratory, Haukeland University Hospital, Bergen, Norway by enzyme-linked immunosorbent assays as described in Emaus et al [<xref rid="R53" ref-type="bibr">53</xref>].</p><p>Vitamin D status was assessed by measuring s-25(OH)D levels. Ultra performance liquid chromatography with tandem mass spectrometry detection (LC-MS/MS) was applied for the analysis. The applied experimental method was developed at NIFES based on the method described by Kissmeyer et al [<xref rid="R54" ref-type="bibr">54</xref>].</p><p>Fatty acids composition of total RBC was determined at NIFES by ultrafast gas chromatographic (UFGC) (Thermo Electron Corporation, Massachusetts, USA) developed by Araujo et al [<xref rid="R55" ref-type="bibr">55</xref>]. The fatty acids composition was calculated using an integrator (Chromeleon 6.80, Dionex Corporation, California, USA) connected to the UFGC and identification ascertained by standard mixtures of methyl esters (Nu-Chek, Minnesota, USA). The RBC analyses are described in details by Markhus et al [<xref rid="R56" ref-type="bibr">56</xref>]. The omega-3 index is the percent of EPA and DHA in RBC membranes expressed as percent of total fatty acids [<xref rid="R39" ref-type="bibr">39</xref>].</p><p>Urinary creatinine was assessed according to routine methodology at NIFES as described by Julshamn et al [<xref rid="R57" ref-type="bibr">57</xref>]. Urinary creatinine was measured spectrophotometerically (Technicon RA 1000) together with a standard reference material (Bayer Testpoint<sup>TM</sup> assayed chemistry control 1).</p><p>S-bile acids, hydroxybutyrat, free fatty acids, glucose, glycerol, HDL, LDL and total cholesterol, lactate, triglycerides were assessed at NIFES according to Aadland et al [<xref rid="R58" ref-type="bibr">58</xref>].</p><p>Serum PTH, Urinary NTx/creatinine and urinary DPYD/creatinine were assessed according to routine methodology at Aker University Hospital, Oslo, Norway.</p></sec></sec><sec id="s4_8"><title>Bone mineral density, body composition and body mass index</title><p>The total body BMD, total body soft tissue composition (fat mass and lean mass) measurements, and weight were performed using dual-energy X-ray absorptiometry (DXA) on a stationary fan beam densitometer (Hologic; QDR4500A) at the Center of Clinical Trials. All measurements were done on the same DXA machine by one trained technician. Percentage fat mass was calculated as fat mass in kilogram in percent of total body weight in kilogram. BMI was calculated as weight (kg) divided by height squared (m<sup>2</sup>). Height was measured by a big ruler.</p></sec><sec id="s4_9"><title>Nutrition, physical activity, smoking and side effects</title><p>Information about nutrition, physical activity and smoking were obtained at the same time as the DXA-assessments and sampling of blood and urine.</p><p>Dietary habits the last three months were determined using two validated food frequency questionnaires (FFQ), &#x0201c;What do you eat?&#x0201d; [<xref rid="R59" ref-type="bibr">59</xref>] and &#x0201c;Seafood intake&#x0201d; [<xref rid="R60" ref-type="bibr">60</xref>]. The completion of the questionnaires was done by the participants with a nutritionist available nearby for possible explanations to questions the participants might have. One of the FFQs (&#x0201c;What do you eat&#x0201d;) was read optically, and a database and a software system (KBS software, version 3.2; University of Oslo, Norway) developed at the Department of Nutrition, University of Oslo, was used to calculate the dietary intake. Total energy intake (EI, kcal), and intake of macronutrients (proteins, lipids and carbohydrates) and micronutrients (minerals and vitamins) were estimated and compared with dietary reference intakes (RDIs). We previously calculated a seafood index which was used for presentation of the pre-intervention results of &#x0201c;seafood dinner&#x0201d;, &#x0201c;seafood other than dinner&#x0201d;, and &#x0201c;fish oil supplements&#x0201d;. These calculations are described in details elsewhere [<xref rid="R56" ref-type="bibr">56</xref>].</p><p>Information of physical activity and current smoking were obtained from the &#x0201c;Seafood intake&#x0201d; questionnaire. However, data on physical activity is not included (no statistical differences were observed between the groups).</p><p>In addition, the participants reported changes due to dietary eating patterns during the intervention period retrospectively, as well as registration of side effects such as stomach upsets, including abdominal pain, nausea, bloating, and constipation, and headache, &#x0201c;tasted bad&#x0201d;, dry mouth as well as tiredness were registered in a self-reported questionnaire which the participants filled out after the intervention period.</p></sec><sec id="s4_10"><title>Statistical analyses</title><p>Continuous variables are expressed as median with IQR, and mean with standard deviation (SD), and the categorical variable current smoking as numbers and percentages. At pre-intervention, one-way analysis of variance was used for continuous normal distributed variables for comparisons between the intervention groups. Kruskal-Wallis test was used for continuous skewed disturbed variables (PTH, BMI, energy intake, and all other kind of food intake as presented, and Chi-square test for the categorical variable current smoking for comparisons between the intervention groups at pre-intervention, as well as for comparison of compliance, dietary patterns and side effects between the intervention groups. Paired-samples t-test was used for calculations of pre-and post-intervention results within each group. In addition, the effect sizes (Eta squared) for the paired-samples t-test results were calculated. General linear model analyses without and with adjustments for the current pre-variable were performed for the delta results in comparison between the intervention groups, and pairwise group comparisons with Bonferroni correction were done if overall p-value was significant. Urinary NTx, DPYD, s-osteocalcin, GLU/GLA ratio, s-25(OH)D, EPA and DHA were also presented using box-plots, and in addition to median, the 25<sup>th</sup> and the 75<sup>th</sup> percentile were given. All analyses covers the 122 included participants.</p><p>Two-tailed <italic>p</italic> values &#x0003c;0.05 were considered statistically significant. The analyses were performed using the Statistical Package for the Social Sciences (SPSS) for windows (IBM SPSS Statistics 23, Chicago, IL, USA, <ext-link ext-link-type="uri" xlink:href="http://www.spss.com">www.spss.com</ext-link>).</p></sec></sec></body><back><ack><p>The authors express appreciation to the study participants and we are grateful for the assistance from Anne-Karin Syversen and laboratory staff at NIFES and at the Center of Clinical Trials.</p><p>The authors' responsibilities: IEG: planning, concept and design of the study, data collection, statistical data analyses, data interpretation, literature search, and preparation of the manuscript. J&#x000d8;: statistical data analyses, data interpretation, literature search, and the major preparation of the first draft of the manuscript. MK: planning, concept and design of the study, data collection, data interpretation, and critical revision of the manuscript. LF: planning, concept and design of the study, data interpretation, and critical revision of the manuscript. CGG: planning, concept and design of the study, data collection, data interpretation, and critical revision of the manuscript. BA: data collection, data interpretation, and critical revision of the manuscript. GR: planning, feed production, data interpretation, and critical revision of the manuscript. &#x000d8;L: planning, concept and design of the study, data interpretation, and critical revision of the manuscript.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICTS OF INTEREST</bold></p><p>Rosenlund is employed by Skretting Aquaculture Research Centre AS which is the central R&#x00026;D unit for the global aquaculture feed company Skretting. Rosenlund was not involved in on-site data collection. All other authors state that they have no conflict of interest.</p></fn><fn fn-type="supported-by"><p><bold>GRANT SUPPORT</bold></p><p>Supported by the Research Council of Norway (165251), Norwegian Women's Public Health Association and National Institute of Nutrition and Seafood Research (measurements and analyses), Skretting Aquaculture Research Centre (feed production and packing of salmon to the study meals).</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lips</surname><given-names>P</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name><name><surname>van Schoor</surname><given-names>NM</given-names></name><name><surname>Vanderschueren</surname><given-names>D</given-names></name><name><surname>Verschueren</surname><given-names>S</given-names></name><name><surname>Kuchuk</surname><given-names>N</given-names></name><name><surname>Milisen</surname><given-names>K</given-names></name><name><surname>Boonen</surname><given-names>S</given-names></name></person-group><article-title>Reducing fracture risk with calcium and vitamin D</article-title><source>Clin Endocrinol (Oxf)</source><year>2010</year><volume>73</volume><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">20796001</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hilger</surname><given-names>J</given-names></name><name><surname>Friedel</surname><given-names>A</given-names></name><name><surname>Herr</surname><given-names>R</given-names></name><name><surname>Rausch</surname><given-names>T</given-names></name><name><surname>Roos</surname><given-names>F</given-names></name><name><surname>Wahl</surname><given-names>DA</given-names></name><name><surname>Pierroz</surname><given-names>DD</given-names></name><name><surname>Weber</surname><given-names>P</given-names></name><name><surname>Hoffmann</surname><given-names>K</given-names></name></person-group><article-title>A systematic review of vitamin D status in populations worldwide</article-title><source>Br J Nutr</source><year>2014</year><volume>111</volume><fpage>23</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">23930771</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cashman</surname><given-names>KD</given-names></name><name><surname>Dowling</surname><given-names>KG</given-names></name><name><surname>Skrabakova</surname><given-names>Z</given-names></name><name><surname>Gonzalez-Gross</surname><given-names>M</given-names></name><name><surname>Valtuena</surname><given-names>J</given-names></name><name><surname>De Henauw</surname><given-names>S</given-names></name><name><surname>Moreno</surname><given-names>L</given-names></name><name><surname>Damsgaard</surname><given-names>CT</given-names></name><name><surname>Michaelsen</surname><given-names>KF</given-names></name><name><surname>Molgaard</surname><given-names>C</given-names></name><name><surname>Jorde</surname><given-names>R</given-names></name><name><surname>Grimnes</surname><given-names>G</given-names></name><name><surname>Moschonis</surname><given-names>G</given-names></name><etal/></person-group><article-title>Vitamin D deficiency in Europe: pandemic?</article-title><source>Am J Clin Nutr</source><year>2016</year><volume>103</volume><fpage>1033</fpage><lpage>1044</lpage><pub-id pub-id-type="pmid">26864360</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="web"><person-group person-group-type="author"><collab>NIFES</collab></person-group><year>2015</year><article-title>Vitamin D</article-title><ext-link ext-link-type="uri" xlink:href="http://nifes.no/en/research-topics/seafood-and-health/seafood-contains/vitamin-d/">http://nifes.no/en/research-topics/seafood-and-health/seafood-contains/vitamin-d/</ext-link></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kettler</surname><given-names>DB</given-names></name></person-group><article-title>Can manipulation of the ratios of essential fatty acids slow the rapid rate of postmenopausal bone loss?</article-title><source>Altern Med Rev</source><year>2001</year><volume>6</volume><fpage>61</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">11207457</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albertazzi</surname><given-names>P</given-names></name><name><surname>Coupland</surname><given-names>K</given-names></name></person-group><article-title>Polyunsaturated fatty acids. Is there a role in postmenopausal osteoporosis prevention?</article-title><source>Maturitas</source><year>2002</year><volume>42</volume><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12020975</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Johnell</surname><given-names>O</given-names></name><name><surname>De Laet</surname><given-names>C</given-names></name><name><surname>Jonsson</surname><given-names>B</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>Ogelsby</surname><given-names>AK</given-names></name></person-group><article-title>International variations in hip fracture probabilities: implications for risk assessment</article-title><source>Journal of bone and mineral research</source><year>2002</year><volume>17</volume><fpage>1237</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">12096837</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunt</surname><given-names>M</given-names></name><name><surname>Felsenberg</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>J</given-names></name><name><surname>Benevolenskaya</surname><given-names>LI</given-names></name><name><surname>Cannata</surname><given-names>JB</given-names></name><name><surname>Dequeker</surname><given-names>J</given-names></name><name><surname>Dodenhof</surname><given-names>C</given-names></name><name><surname>Falch</surname><given-names>JA</given-names></name><name><surname>Johnell</surname><given-names>O</given-names></name><name><surname>Khaw</surname><given-names>K</given-names></name><name><surname>Masaryk</surname><given-names>P</given-names></name><name><surname>Pols</surname><given-names>HA</given-names></name><name><surname>Poor</surname><given-names>G</given-names></name><etal/></person-group><article-title>Population-based geographic variations in DXA bone density in Europe: the EVOS study. European Vertebral Osteoporosis</article-title><source>Osteoporosis international</source><year>1997</year><volume>7</volume><fpage>175</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">9205628</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omsland</surname><given-names>TK</given-names></name><name><surname>Holvik</surname><given-names>K</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Center</surname><given-names>JR</given-names></name><name><surname>Emaus</surname><given-names>N</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name><name><surname>Schei</surname><given-names>B</given-names></name><name><surname>Tverdal</surname><given-names>A</given-names></name><name><surname>Gjesdal</surname><given-names>CG</given-names></name><name><surname>Grimnes</surname><given-names>G</given-names></name><name><surname>Forsmo</surname><given-names>S</given-names></name><name><surname>Eisman</surname><given-names>JA</given-names></name><name><surname>Sogaard</surname><given-names>AJ</given-names></name></person-group><article-title>Hip fractures in Norway 1999-2008: time trends in total incidence and second hip fracture rates. A NOREPOS study</article-title><source>Eur J Epidemiol</source><year>2012</year><volume>27</volume><fpage>807</fpage><lpage>814</lpage><pub-id pub-id-type="pmid">22870851</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyen</surname><given-names>J</given-names></name><name><surname>Apalset</surname><given-names>EM</given-names></name><name><surname>Gjesdal</surname><given-names>CG</given-names></name><name><surname>Brudvik</surname><given-names>C</given-names></name><name><surname>Lie</surname><given-names>SA</given-names></name><name><surname>Hove</surname><given-names>LM</given-names></name></person-group><article-title>Vitamin D inadequacy is associated with low-energy distal radius fractures: a case-control study</article-title><source>Bone</source><year>2011</year><volume>48</volume><fpage>1140</fpage><lpage>1145</lpage><pub-id pub-id-type="pmid">21295169</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holvik</surname><given-names>K</given-names></name><name><surname>Ahmed</surname><given-names>LA</given-names></name><name><surname>Forsmo</surname><given-names>S</given-names></name><name><surname>Gjesdal</surname><given-names>CG</given-names></name><name><surname>Grimnes</surname><given-names>G</given-names></name><name><surname>Samuelsen</surname><given-names>SO</given-names></name><name><surname>Schei</surname><given-names>B</given-names></name><name><surname>Blomhoff</surname><given-names>R</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name></person-group><article-title>Low serum levels of 25-hydroxyvitamin D predict hip fracture in the elderly: a NOREPOS study</article-title><source>The Journal of clinical endocrinology and metabolism</source><year>2013</year><volume>98</volume><fpage>3341</fpage><lpage>3350</lpage><pub-id pub-id-type="pmid">23678033</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avenell</surname><given-names>A</given-names></name><name><surname>Mak</surname><given-names>JC</given-names></name><name><surname>O'Connell</surname><given-names>D</given-names></name></person-group><article-title>Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men</article-title><source>Cochrane Database Syst Rev</source><year>2014</year><volume>4</volume><fpage>CD000227</fpage></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name></person-group><article-title>Vitamin D: evolutionary, physiological and health perspectives</article-title><source>Curr Drug Targets</source><year>2011</year><volume>12</volume><fpage>4</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">20795941</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmas</surname><given-names>PD</given-names></name><name><surname>Eastell</surname><given-names>R</given-names></name><name><surname>Garnero</surname><given-names>P</given-names></name><name><surname>Seibel</surname><given-names>MJ</given-names></name><name><surname>Stepan</surname><given-names>J</given-names></name></person-group><article-title>The use of biochemical markers of bone turnover in osteoporosis</article-title><source>Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporosis international</source><year>2000</year><volume>11</volume><issue>Suppl 6</issue><fpage>S2</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">11193237</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gundberg</surname><given-names>CM</given-names></name><name><surname>Lian</surname><given-names>JB</given-names></name><name><surname>Booth</surname><given-names>SL</given-names></name></person-group><article-title>Vitamin K-dependent carboxylation of osteocalcin: friend or foe?</article-title><source>Adv Nutr</source><year>2012</year><volume>3</volume><fpage>149</fpage><lpage>157</lpage><pub-id pub-id-type="pmid">22516722</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vermeer</surname><given-names>C</given-names></name></person-group><article-title>Vitamin K: the effect on health beyond coagulation - an overview</article-title><source>Food Nutr Res</source><year>2012</year><fpage>56</fpage></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guralp</surname><given-names>O</given-names></name><name><surname>Erel</surname><given-names>CT</given-names></name></person-group><article-title>Effects of vitamin K in postmenopausal women: mini review</article-title><source>Maturitas</source><year>2014</year><volume>77</volume><fpage>294</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">24342502</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>AM</given-names></name><name><surname>Tile</surname><given-names>L</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Tomlinson</surname><given-names>G</given-names></name><name><surname>Hawker</surname><given-names>G</given-names></name><name><surname>Scher</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Vieth</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>L</given-names></name><name><surname>Jamal</surname><given-names>S</given-names></name><name><surname>Josse</surname><given-names>R</given-names></name></person-group><article-title>Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>e196</fpage><pub-id pub-id-type="pmid">18922041</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodges</surname><given-names>SJ</given-names></name><name><surname>Akesson</surname><given-names>K</given-names></name><name><surname>Vergnaud</surname><given-names>P</given-names></name><name><surname>Obrant</surname><given-names>K</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name></person-group><article-title>Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture</article-title><source>Journal of bone and mineral research</source><year>1993</year><volume>8</volume><fpage>1241</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">8256661</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamatani</surname><given-names>M</given-names></name><name><surname>Morimoto</surname><given-names>S</given-names></name><name><surname>Nakajima</surname><given-names>M</given-names></name><name><surname>Fukuo</surname><given-names>K</given-names></name><name><surname>Onishi</surname><given-names>T</given-names></name><name><surname>Kitano</surname><given-names>S</given-names></name><name><surname>Niinobu</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>Decreased circulating levels of vitamin K and 25-hydroxyvitamin D in osteopenic elderly men</article-title><source>Metabolism</source><year>1998</year><volume>47</volume><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">9472970</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apalset</surname><given-names>EM</given-names></name><name><surname>Gjesdal</surname><given-names>CG</given-names></name><name><surname>Eide</surname><given-names>GE</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name></person-group><article-title>Intake of vitamin K1 and K2 and risk of hip fractures: The Hordaland Health Study</article-title><source>Bone</source><year>2011</year><volume>49</volume><fpage>990</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">21839190</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Apalset</surname><given-names>EM</given-names></name><name><surname>Gjesdal</surname><given-names>CG</given-names></name><name><surname>Eide</surname><given-names>GE</given-names></name><name><surname>Johansen</surname><given-names>A-MW</given-names></name><name><surname>Drevon</surname><given-names>CA</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name></person-group><article-title>Dietary vitamins K1, K2 and bone mineral density: the Hordaland Health Study</article-title><source>Arch Osteoporos</source><year>2010</year><volume>5</volume><fpage>73</fpage><lpage>81</lpage></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plantalech</surname><given-names>L</given-names></name><name><surname>Guillaumont</surname><given-names>M</given-names></name><name><surname>Vergnaud</surname><given-names>P</given-names></name><name><surname>Leclercq</surname><given-names>M</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name></person-group><article-title>Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women</article-title><source>Journal of bone and mineral research</source><year>1991</year><volume>6</volume><fpage>1211</fpage><lpage>1216</lpage><pub-id pub-id-type="pmid">1666807</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szulc</surname><given-names>P</given-names></name><name><surname>Chapuy</surname><given-names>MC</given-names></name><name><surname>Meunier</surname><given-names>PJ</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name></person-group><article-title>Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women</article-title><source>J Clin Invest</source><year>1993</year><volume>91</volume><fpage>1769</fpage><lpage>1774</lpage><pub-id pub-id-type="pmid">8473517</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szulc</surname><given-names>P</given-names></name><name><surname>Arlot</surname><given-names>M</given-names></name><name><surname>Chapuy</surname><given-names>MC</given-names></name><name><surname>Duboeuf</surname><given-names>F</given-names></name><name><surname>Meunier</surname><given-names>PJ</given-names></name><name><surname>Delmas</surname><given-names>PD</given-names></name></person-group><article-title>Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women</article-title><source>Journal of bone and mineral research</source><year>1994</year><volume>9</volume><fpage>1591</fpage><lpage>1595</lpage><pub-id pub-id-type="pmid">7817805</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsunaga</surname><given-names>S</given-names></name><name><surname>Ito</surname><given-names>H</given-names></name><name><surname>Sakou</surname><given-names>T</given-names></name></person-group><article-title>The effect of vitamin K and D supplementation on ovariectomy-induced bone loss</article-title><source>Calcif Tissue Int</source><year>1999</year><volume>65</volume><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">10485979</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwamoto</surname><given-names>J</given-names></name><name><surname>Takeda</surname><given-names>T</given-names></name><name><surname>Ichimura</surname><given-names>S</given-names></name></person-group><article-title>Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis</article-title><source>J Orthop Sci</source><year>2000</year><volume>5</volume><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">11180916</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ornstrup</surname><given-names>MJ</given-names></name><name><surname>Harslof</surname><given-names>T</given-names></name><name><surname>Kjaer</surname><given-names>TN</given-names></name><name><surname>Langdahl</surname><given-names>BL</given-names></name><name><surname>Pedersen</surname><given-names>SB</given-names></name></person-group><article-title>Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial</article-title><source>The Journal of clinical endocrinology and metabolism</source><year>2014</year><volume>99</volume><fpage>4720</fpage><lpage>4729</lpage><pub-id pub-id-type="pmid">25322274</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JG</given-names></name><name><surname>Shin</surname><given-names>CS</given-names></name><name><surname>Choi</surname><given-names>YM</given-names></name><name><surname>Moon</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name></person-group><article-title>The relationship among circulating insulin-like growth factor components, biochemical markers of bone turnover and bone mineral density in postmenopausal women under the age of 60</article-title><source>Clin Endocrinol (Oxf)</source><year>1999</year><volume>51</volume><fpage>301</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">10469009</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>DC</given-names></name><name><surname>Garnero</surname><given-names>P</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Santora</surname><given-names>A</given-names></name><name><surname>Delmas</surname><given-names>P</given-names></name><name><surname>Ewing</surname><given-names>SK</given-names></name><name><surname>Black</surname><given-names>DM</given-names></name></person-group><article-title>Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial</article-title><source>Journal of bone and mineral research</source><year>2006</year><volume>21</volume><fpage>292</fpage><lpage>299</lpage><pub-id pub-id-type="pmid">16418785</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>LJ</given-names></name></person-group><article-title>Denosumab: a review of its use in postmenopausal women with osteoporosis</article-title><source>Drugs Aging</source><year>2014</year><volume>31</volume><fpage>555</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">24935243</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name></person-group><article-title>Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis</article-title><source>Int J Clin Exp Pathol</source><year>2014</year><volume>7</volume><fpage>2113</fpage><lpage>2122</lpage><pub-id pub-id-type="pmid">24966919</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funck-Brentano</surname><given-names>T</given-names></name><name><surname>Biver</surname><given-names>E</given-names></name><name><surname>Chopin</surname><given-names>F</given-names></name><name><surname>Bouvard</surname><given-names>B</given-names></name><name><surname>Coiffier</surname><given-names>G</given-names></name><name><surname>Souberbielle</surname><given-names>JC</given-names></name><name><surname>Garnero</surname><given-names>P</given-names></name><name><surname>Roux</surname><given-names>C</given-names></name></person-group><article-title>Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review</article-title><source>Semin Arthritis Rheum</source><year>2011</year><volume>41</volume><fpage>157</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">21507464</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graff</surname><given-names>IE</given-names></name><name><surname>H&#x000f8;ie</surname><given-names>S</given-names></name><name><surname>Totland</surname><given-names>GK</given-names></name><name><surname>Lie</surname><given-names>&#x000d8;</given-names></name></person-group><article-title>Three different levels of dietary vitamin D3 fed to first-feeding fry of Atlantic salmon (Salmo salar L.): Effect on growth, mortality, calcium content and bone formation</article-title><source>Aquaculture Nutrition</source><year>2002</year><volume>8</volume><fpage>103</fpage><lpage>111</lpage></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvli</surname><given-names>O</given-names></name><name><surname>Lie</surname><given-names>O</given-names></name><name><surname>Aksnes</surname><given-names>L</given-names></name></person-group><article-title>Tissue distribution of vitamin D-3 in Atlantic salmon Salmo salar: effect of dietary level</article-title><source>Aquaculture Nutrition</source><year>1998</year><volume>4</volume><fpage>127</fpage><lpage>131</lpage></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koshihara</surname><given-names>Y</given-names></name><name><surname>Hoshi</surname><given-names>K</given-names></name><name><surname>Ishibashi</surname><given-names>H</given-names></name><name><surname>Shiraki</surname><given-names>M</given-names></name></person-group><article-title>Vitamin K2 promotes 1alpha,25(OH)2 vitamin D3-induced mineralization in human periosteal osteoblasts</article-title><source>Calcif Tissue Int</source><year>1996</year><volume>59</volume><fpage>466</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">8939773</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finnes</surname><given-names>TE</given-names></name><name><surname>Lofthus</surname><given-names>CM</given-names></name><name><surname>Meyer</surname><given-names>HE</given-names></name><name><surname>Sogaard</surname><given-names>AJ</given-names></name><name><surname>Tell</surname><given-names>GS</given-names></name><name><surname>Apalset</surname><given-names>EM</given-names></name><name><surname>Gjesdal</surname><given-names>C</given-names></name><name><surname>Grimnes</surname><given-names>G</given-names></name><name><surname>Schei</surname><given-names>B</given-names></name><name><surname>Blomhoff</surname><given-names>R</given-names></name><name><surname>Samuelsen</surname><given-names>SO</given-names></name><name><surname>Holvik</surname><given-names>K</given-names></name></person-group><article-title>A combination of low serum concentrations of vitamins K and D is associated with increased risk of hip fractures in elderly Norwegians: a NOREPOS study</article-title><source>Osteoporosis international</source><year>2016</year><volume>27</volume><fpage>1645</fpage><lpage>1652</lpage><pub-id pub-id-type="pmid">26630974</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holick</surname><given-names>MF</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name></person-group><article-title>Vitamin D deficiency: a worldwide problem with health consequences</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>87</volume><fpage>1080S</fpage><lpage>1086S</lpage><pub-id pub-id-type="pmid">18400738</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>WS</given-names></name><name><surname>Von Schacky</surname><given-names>C</given-names></name></person-group><article-title>The Omega-3 Index: a new risk factor for death from coronary heart disease?</article-title><source>Preventive medicine</source><year>2004</year><volume>39</volume><fpage>212</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">15208005</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salari</surname><given-names>P</given-names></name><name><surname>Rezaie</surname><given-names>A</given-names></name><name><surname>Larijani</surname><given-names>B</given-names></name><name><surname>Abdollahi</surname><given-names>M</given-names></name></person-group><article-title>A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis</article-title><source>Med Sci Monit</source><year>2008</year><volume>14</volume><fpage>RA37</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">18301367</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>MC</given-names></name><name><surname>Coetzer</surname><given-names>H</given-names></name><name><surname>de Winter</surname><given-names>R</given-names></name><name><surname>Gericke</surname><given-names>G</given-names></name><name><surname>van Papendorp</surname><given-names>DH</given-names></name></person-group><article-title>Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis</article-title><source>Aging (Milano)</source><year>1998</year><volume>10</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">9932142</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassey</surname><given-names>EJ</given-names></name><name><surname>Littlewood</surname><given-names>JJ</given-names></name><name><surname>Rothwell</surname><given-names>MC</given-names></name><name><surname>Pye</surname><given-names>DW</given-names></name></person-group><article-title>Lack of effect of supplementation with essential fatty acids on bone mineral density in healthy pre- and postmenopausal women: two randomized controlled trials of Efacal v. calcium alone</article-title><source>Br J Nutr</source><year>2000</year><volume>83</volume><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">10911771</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farina</surname><given-names>EK</given-names></name><name><surname>Kiel</surname><given-names>DP</given-names></name><name><surname>Roubenoff</surname><given-names>R</given-names></name><name><surname>Schaefer</surname><given-names>EJ</given-names></name><name><surname>Cupples</surname><given-names>LA</given-names></name><name><surname>Tucker</surname><given-names>KL</given-names></name></person-group><article-title>Protective effects of fish intake and interactive effects of long-chain polyunsaturated fatty acid intakes on hip bone mineral density in older adults: the Framingham Osteoporosis Study</article-title><source>Am J Clin Nutr</source><year>2011</year><volume>93</volume><fpage>1142</fpage><lpage>1151</lpage><pub-id pub-id-type="pmid">21367955</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>GI</given-names></name><name><surname>Julliand</surname><given-names>S</given-names></name><name><surname>Reeds</surname><given-names>DN</given-names></name><name><surname>Sinacore</surname><given-names>DR</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name><name><surname>Mittendorfer</surname><given-names>B</given-names></name></person-group><article-title>Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults</article-title><source>Am J Clin Nutr</source><year>2015</year><volume>102</volume><fpage>115</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">25994567</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarantino</surname><given-names>U</given-names></name><name><surname>Baldi</surname><given-names>J</given-names></name><name><surname>Celi</surname><given-names>M</given-names></name><name><surname>Rao</surname><given-names>C</given-names></name><name><surname>Liuni</surname><given-names>FM</given-names></name><name><surname>Iundusi</surname><given-names>R</given-names></name><name><surname>Gasbarra</surname><given-names>E</given-names></name></person-group><article-title>Osteoporosis and sarcopenia: the connections</article-title><source>Aging Clin Exp Res</source><year>2013</year><volume>25</volume><issue>Suppl 1</issue><fpage>S93</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">24046056</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gingras</surname><given-names>AA</given-names></name><name><surname>White</surname><given-names>PJ</given-names></name><name><surname>Chouinard</surname><given-names>PY</given-names></name><name><surname>Julien</surname><given-names>P</given-names></name><name><surname>Davis</surname><given-names>TA</given-names></name><name><surname>Dombrowski</surname><given-names>L</given-names></name><name><surname>Couture</surname><given-names>Y</given-names></name><name><surname>Dubreuil</surname><given-names>P</given-names></name><name><surname>Myre</surname><given-names>A</given-names></name><name><surname>Bergeron</surname><given-names>K</given-names></name><name><surname>Marette</surname><given-names>A</given-names></name><name><surname>Thivierge</surname><given-names>MC</given-names></name></person-group><article-title>Long-chain omega-3 fatty acids regulate bovine whole-body protein metabolism by promoting muscle insulin signalling to the Akt-mTOR-S6K1 pathway and insulin sensitivity</article-title><source>J Physiol</source><year>2007</year><volume>579</volume><fpage>269</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">17158167</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bischoff</surname><given-names>HA</given-names></name><name><surname>Stahelin</surname><given-names>HB</given-names></name><name><surname>Urscheler</surname><given-names>N</given-names></name><name><surname>Ehrsam</surname><given-names>R</given-names></name><name><surname>Vonthein</surname><given-names>R</given-names></name><name><surname>Perrig-Chiello</surname><given-names>P</given-names></name><name><surname>Tyndall</surname><given-names>A</given-names></name><name><surname>Theiler</surname><given-names>R</given-names></name></person-group><article-title>Muscle strength in the elderly: its relation to vitamin D metabolites</article-title><source>Arch Phys Med Rehabil</source><year>1999</year><volume>80</volume><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">9915372</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhesi</surname><given-names>JK</given-names></name><name><surname>Bearne</surname><given-names>LM</given-names></name><name><surname>Moniz</surname><given-names>C</given-names></name><name><surname>Hurley</surname><given-names>MV</given-names></name><name><surname>Jackson</surname><given-names>SH</given-names></name><name><surname>Swift</surname><given-names>CG</given-names></name><name><surname>Allain</surname><given-names>TJ</given-names></name></person-group><article-title>Neuromuscular and psychomotor function in elderly subjects who fall and the relationship with vitamin D status</article-title><source>Journal of bone and mineral research</source><year>2002</year><volume>17</volume><fpage>891</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">12009020</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>Johnell</surname><given-names>O</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>De Laet</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Burckhardt</surname><given-names>P</given-names></name><name><surname>Cooper</surname><given-names>C</given-names></name><name><surname>Christiansen</surname><given-names>C</given-names></name><name><surname>Cummings</surname><given-names>S</given-names></name><name><surname>Eisman</surname><given-names>JA</given-names></name><name><surname>Fujiwara</surname><given-names>S</given-names></name><name><surname>Gluer</surname><given-names>C</given-names></name><etal/></person-group><article-title>The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women</article-title><source>Osteoporosis international</source><year>2007</year><volume>18</volume><fpage>1033</fpage><lpage>1046</lpage><pub-id pub-id-type="pmid">17323110</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanis</surname><given-names>JA</given-names></name><name><surname>McCloskey</surname><given-names>EV</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>Melton</surname><given-names>LJ</given-names><suffix>3rd</suffix></name><name><surname>Khaltaev</surname><given-names>N</given-names></name></person-group><article-title>A reference standard for the description of osteoporosis</article-title><source>Bone</source><year>2008</year><volume>42</volume><issue>3</issue><fpage>467</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">18180210</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Nasjonalt Folkehelseinstitutt</collab></person-group><year>2005</year><source>Standard operasjonsprosedyre</source><publisher-name>Randomisering</publisher-name><publisher-loc>Oslo, Norway</publisher-loc></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Berg</surname><given-names>M</given-names></name><name><surname>Birnbaum</surname><given-names>LS</given-names></name><name><surname>Denison</surname><given-names>M</given-names></name><name><surname>De Vito</surname><given-names>M</given-names></name><name><surname>Farland</surname><given-names>W</given-names></name><name><surname>Feeley</surname><given-names>M</given-names></name><name><surname>Fiedler</surname><given-names>H</given-names></name><name><surname>Hakansson</surname><given-names>H</given-names></name><name><surname>Hanberg</surname><given-names>A</given-names></name><name><surname>Haws</surname><given-names>L</given-names></name><name><surname>Rose</surname><given-names>M</given-names></name><name><surname>Safe</surname><given-names>S</given-names></name><name><surname>Schrenk</surname><given-names>D</given-names></name><etal/></person-group><article-title>The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds</article-title><source>Toxicol Sci</source><year>2006</year><volume>93</volume><fpage>223</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">16829543</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emaus</surname><given-names>N</given-names></name><name><surname>Gjesdal</surname><given-names>CG</given-names></name><name><surname>Almas</surname><given-names>B</given-names></name><name><surname>Christensen</surname><given-names>M</given-names></name><name><surname>Grimsgaard</surname><given-names>AS</given-names></name><name><surname>Berntsen</surname><given-names>GK</given-names></name><name><surname>Salomonsen</surname><given-names>L</given-names></name><name><surname>Fonnebo</surname><given-names>V</given-names></name></person-group><article-title>Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial</article-title><source>Osteoporosis international</source><year>2010</year><volume>21</volume><fpage>1731</fpage><lpage>1740</lpage><pub-id pub-id-type="pmid">19937427</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kissmeyer</surname><given-names>AM</given-names></name><name><surname>Sonne</surname><given-names>K</given-names></name><name><surname>Binderup</surname><given-names>E</given-names></name></person-group><article-title>Determination of the vitamin D analog EB 1089 (seocalcitol) in human and pig serum using liquid chromatography-tandem mass spectrometry</article-title><source>J Chromatogr B Biomed Sci Appl</source><year>2000</year><volume>740</volume><fpage>117</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">10798301</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araujo</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><name><surname>Froyland</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>JX</given-names></name></person-group><article-title>Evaluation of a rapid method for the quantitative analysis of fatty acids in various matrices</article-title><source>J Chromatogr A</source><year>2008</year><volume>1212</volume><fpage>106</fpage><lpage>113</lpage><pub-id pub-id-type="pmid">18937951</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markhus</surname><given-names>MW</given-names></name><name><surname>Graff</surname><given-names>IE</given-names></name><name><surname>Dahl</surname><given-names>L</given-names></name><name><surname>Seldal</surname><given-names>CF</given-names></name><name><surname>Skotheim</surname><given-names>S</given-names></name><name><surname>Braarud</surname><given-names>HC</given-names></name><name><surname>Stormark</surname><given-names>KM</given-names></name><name><surname>Malde</surname><given-names>MK</given-names></name></person-group><article-title>Establishment of a seafood index to assess the seafood consumption in pregnant women</article-title><source>Food Nutr Res</source><year>2013</year><fpage>57</fpage></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Julshamn</surname><given-names>K</given-names></name><name><surname>Dahl</surname><given-names>L</given-names></name><name><surname>Eckhoff</surname><given-names>K</given-names></name></person-group><article-title>Determination of iodine in seafood by inductively coupled plasma/mass spectrometry</article-title><source>J AOAC Int</source><year>2001</year><volume>84</volume><fpage>1976</fpage><lpage>1983</lpage><pub-id pub-id-type="pmid">11767171</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aadland</surname><given-names>EK</given-names></name><name><surname>Lavigne</surname><given-names>C</given-names></name><name><surname>Graff</surname><given-names>IE</given-names></name><name><surname>Eng</surname><given-names>O</given-names></name><name><surname>Paquette</surname><given-names>M</given-names></name><name><surname>Holthe</surname><given-names>A</given-names></name><name><surname>Mellgren</surname><given-names>G</given-names></name><name><surname>Jacques</surname><given-names>H</given-names></name><name><surname>Liaset</surname><given-names>B</given-names></name></person-group><article-title>Lean-seafood intake reduces cardiovascular lipid risk factors in healthy subjects: results from a randomized controlled trial with a crossover design</article-title><source>Am J Clin Nutr</source><year>2015</year><volume>102</volume><fpage>582</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">26224298</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsen</surname><given-names>MH</given-names></name><name><surname>Lillegaard</surname><given-names>IT</given-names></name><name><surname>Karlsen</surname><given-names>A</given-names></name><name><surname>Blomhoff</surname><given-names>R</given-names></name><name><surname>Drevon</surname><given-names>CA</given-names></name><name><surname>Andersen</surname><given-names>LF</given-names></name></person-group><article-title>Evaluation of energy and dietary intake estimates from a food frequency questionnaire using independent energy expenditure measurement and weighed food records</article-title><source>Nutr J</source><year>2010</year><volume>9</volume><fpage>37</fpage><pub-id pub-id-type="pmid">20843361</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>L</given-names></name><name><surname>Maeland</surname><given-names>CA</given-names></name><name><surname>Bjorkkjaer</surname><given-names>T</given-names></name></person-group><article-title>A short food frequency questionnaire to assess intake of seafood and n-3 supplements: validation with biomarkers</article-title><source>Nutr J</source><year>2011</year><volume>10</volume><fpage>127</fpage><pub-id pub-id-type="pmid">22099052</pub-id></element-citation></ref></ref-list></back></article>